x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Ireland
|
|
98-1088325
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Large accelerated filer
|
|
x
|
|
|
Accelerated filer
|
|
o
|
Non-accelerated filer
|
|
o
|
(Do not check if smaller reporting company)
|
|
Smaller reporting company
|
|
o
|
|
|
|
|
|
Emerging growth company
|
|
o
|
|
|
Page
|
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
|
||
|
|
|
Item 1.
|
Financial Statements.
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
Net sales
|
$
|
824.5
|
|
|
$
|
866.6
|
|
|
$
|
1,635.4
|
|
|
$
|
1,682.4
|
|
Cost of sales
|
408.4
|
|
|
377.8
|
|
|
800.7
|
|
|
768.5
|
|
||||
Gross profit
|
416.1
|
|
|
488.8
|
|
|
834.7
|
|
|
913.9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Selling, general and administrative expenses
|
232.1
|
|
|
224.9
|
|
|
540.2
|
|
|
434.2
|
|
||||
Research and development expenses
|
69.2
|
|
|
74.8
|
|
|
131.4
|
|
|
132.9
|
|
||||
Restructuring charges, net
|
0.6
|
|
|
14.0
|
|
|
17.8
|
|
|
22.4
|
|
||||
Non-restructuring impairment charges
|
—
|
|
|
—
|
|
|
—
|
|
|
16.9
|
|
||||
Losses (gains) on divestiture and license
|
2.1
|
|
|
—
|
|
|
(57.0
|
)
|
|
—
|
|
||||
Operating income
|
112.1
|
|
|
175.1
|
|
|
202.3
|
|
|
307.5
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Interest expense
|
(92.2
|
)
|
|
(95.6
|
)
|
|
(186.4
|
)
|
|
(192.8
|
)
|
||||
Interest income
|
0.6
|
|
|
0.4
|
|
|
1.5
|
|
|
0.6
|
|
||||
Other income (expense), net
|
10.0
|
|
|
(1.3
|
)
|
|
2.5
|
|
|
(2.0
|
)
|
||||
Income from continuing operations before income taxes
|
30.5
|
|
|
78.6
|
|
|
19.9
|
|
|
113.3
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Income tax benefit
|
(40.1
|
)
|
|
(98.1
|
)
|
|
(79.6
|
)
|
|
(161.9
|
)
|
||||
Income from continuing operations
|
70.6
|
|
|
176.7
|
|
|
99.5
|
|
|
275.2
|
|
||||
|
|
|
|
|
|
|
|
||||||||
(Loss) income from discontinued operations, net of income taxes
|
(7.8
|
)
|
|
22.6
|
|
|
362.5
|
|
|
42.4
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
62.8
|
|
|
$
|
199.3
|
|
|
$
|
462.0
|
|
|
$
|
317.6
|
|
|
|
|
|
|
|
|
|
||||||||
Basic earnings per share (Note 7):
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations
|
$
|
0.72
|
|
|
$
|
1.63
|
|
|
$
|
0.99
|
|
|
$
|
2.50
|
|
(Loss) income from discontinued operations
|
(0.08
|
)
|
|
0.21
|
|
|
3.59
|
|
|
0.39
|
|
||||
Net income
|
$
|
0.64
|
|
|
$
|
1.84
|
|
|
$
|
4.58
|
|
|
$
|
2.89
|
|
|
|
|
|
|
|
|
|
||||||||
Basic weighted-average shares outstanding
|
98.5
|
|
|
108.6
|
|
|
100.9
|
|
|
109.9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Diluted earnings per share (Note 7):
|
|
|
|
|
|
|
|
||||||||
Income from continuing operations
|
$
|
0.72
|
|
|
$
|
1.62
|
|
|
$
|
0.98
|
|
|
$
|
2.48
|
|
(Loss) income from discontinued operations
|
(0.08
|
)
|
|
0.21
|
|
|
3.58
|
|
|
0.38
|
|
||||
Net income
|
$
|
0.64
|
|
|
$
|
1.82
|
|
|
$
|
4.57
|
|
|
$
|
2.87
|
|
|
|
|
|
|
|
|
|
||||||||
Diluted weighted-average shares outstanding
|
98.7
|
|
|
109.4
|
|
|
101.2
|
|
|
110.8
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
Net income
|
$
|
62.8
|
|
|
$
|
199.3
|
|
|
$
|
462.0
|
|
|
$
|
317.6
|
|
Other comprehensive income (loss), net of tax:
|
|
|
|
|
|
|
|
||||||||
Currency translation adjustments
|
5.0
|
|
|
(1.2
|
)
|
|
7.4
|
|
|
7.6
|
|
||||
Unrecognized gain on derivatives, net of ($0.2), $-, ($0.2) and $- tax
|
0.4
|
|
|
0.2
|
|
|
0.6
|
|
|
0.4
|
|
||||
Unrecognized (loss) gain on benefit plans, net of $-, ($0.3), ($31.4) and $5.1 tax
|
(0.7
|
)
|
|
0.4
|
|
|
45.9
|
|
|
(8.4
|
)
|
||||
Unrecognized (loss) gain on investments, net of $-, $-, $- and $- tax
|
(2.8
|
)
|
|
—
|
|
|
10.6
|
|
|
—
|
|
||||
Total other comprehensive income (loss), net of tax
|
1.9
|
|
|
(0.6
|
)
|
|
64.5
|
|
|
(0.4
|
)
|
||||
Comprehensive Income
|
$
|
64.7
|
|
|
$
|
198.7
|
|
|
$
|
526.5
|
|
|
$
|
317.2
|
|
|
June 30,
2017 |
|
December 30,
2016 |
||||
Assets
|
|
|
|
||||
Current Assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
330.2
|
|
|
$
|
342.0
|
|
Accounts receivable, less allowance for doubtful accounts of $4.0 and $4.0
|
482.1
|
|
|
431.0
|
|
||
Inventories
|
339.4
|
|
|
350.7
|
|
||
Prepaid expenses and other current assets
|
134.0
|
|
|
131.9
|
|
||
Notes receivable
|
154.0
|
|
|
—
|
|
||
Current assets held for sale
|
—
|
|
|
310.9
|
|
||
Total current assets
|
1,439.7
|
|
|
1,566.5
|
|
||
Property, plant and equipment, net
|
940.7
|
|
|
881.5
|
|
||
Goodwill
|
3,446.2
|
|
|
3,498.1
|
|
||
Intangible assets, net
|
8,604.7
|
|
|
9,000.5
|
|
||
Other assets
|
189.9
|
|
|
259.7
|
|
||
Total Assets
|
$
|
14,621.2
|
|
|
$
|
15,206.3
|
|
|
|
|
|
||||
Liabilities and Shareholders' Equity
|
|
|
|
||||
Current Liabilities:
|
|
|
|
||||
Current maturities of long-term debt
|
$
|
519.4
|
|
|
$
|
271.2
|
|
Accounts payable
|
113.9
|
|
|
112.1
|
|
||
Accrued payroll and payroll-related costs
|
92.8
|
|
|
76.1
|
|
||
Accrued interest
|
54.1
|
|
|
68.7
|
|
||
Income taxes payable
|
122.0
|
|
|
101.7
|
|
||
Accrued and other current liabilities
|
460.2
|
|
|
557.1
|
|
||
Current liabilities held for sale
|
—
|
|
|
120.3
|
|
||
Total current liabilities
|
1,362.4
|
|
|
1,307.2
|
|
||
Long-term debt
|
5,338.5
|
|
|
5,880.8
|
|
||
Pension and postretirement benefits
|
67.7
|
|
|
136.4
|
|
||
Environmental liabilities
|
73.6
|
|
|
73.0
|
|
||
Deferred income taxes
|
2,254.4
|
|
|
2,398.1
|
|
||
Other income tax liabilities
|
67.5
|
|
|
70.4
|
|
||
Other liabilities
|
361.1
|
|
|
356.1
|
|
||
Total Liabilities
|
9,525.2
|
|
|
10,222.0
|
|
||
Shareholders' Equity:
|
|
|
|
||||
Preferred shares, $0.20 par value, 500,000,000 authorized; none issued and outstanding
|
—
|
|
|
—
|
|
||
Ordinary A shares, €1.00 par value, 40,000 authorized; none issued and outstanding
|
—
|
|
|
—
|
|
||
Ordinary shares, $0.20 par value, 500,000,000 authorized; 118,646,325 and 118,182,944 issued;
97,138,549 and 104,667,545 outstanding
|
23.7
|
|
|
23.6
|
|
||
Ordinary shares held in treasury at cost, 21,507,776 and 13,515,399
|
(1,296.9
|
)
|
|
(919.8
|
)
|
||
Additional paid-in capital
|
5,459.7
|
|
|
5,424.0
|
|
||
Retained earnings
|
917.5
|
|
|
529.0
|
|
||
Accumulated other comprehensive loss
|
(8.0
|
)
|
|
(72.5
|
)
|
||
Total Shareholders' Equity
|
5,096.0
|
|
|
4,984.3
|
|
||
Total Liabilities and Shareholders' Equity
|
$
|
14,621.2
|
|
|
$
|
15,206.3
|
|
|
Six Months Ended
|
||||||
|
June 30,
2017 |
|
June 24,
2016 |
||||
Cash Flows From Operating Activities:
|
|
|
|
||||
Net income
|
$
|
462.0
|
|
|
$
|
317.6
|
|
Adjustments to reconcile net cash from operating activities:
|
|
|
|
||||
Depreciation and amortization
|
406.0
|
|
|
419.0
|
|
||
Share-based compensation
|
31.8
|
|
|
22.1
|
|
||
Deferred income taxes
|
(157.6
|
)
|
|
(215.4
|
)
|
||
Non-cash impairment charges
|
—
|
|
|
16.9
|
|
||
Gain on divestitures
|
(419.1
|
)
|
|
(2.1
|
)
|
||
Other non-cash items
|
32.4
|
|
|
18.6
|
|
||
Changes in assets and liabilities, net of the effects of acquisitions:
|
|
|
|
||||
Accounts receivable, net
|
(52.6
|
)
|
|
(17.2
|
)
|
||
Inventories
|
(8.5
|
)
|
|
8.0
|
|
||
Accounts payable
|
(10.7
|
)
|
|
4.4
|
|
||
Income taxes
|
12.5
|
|
|
58.4
|
|
||
Other
|
(73.7
|
)
|
|
52.7
|
|
||
Net cash from operating activities
|
222.5
|
|
|
683.0
|
|
||
Cash Flows From Investing Activities:
|
|
|
|
||||
Capital expenditures
|
(101.6
|
)
|
|
(84.5
|
)
|
||
Acquisitions and intangibles, net of cash acquired
|
—
|
|
|
(169.5
|
)
|
||
Proceeds from divestitures, net of cash
|
576.9
|
|
|
3.0
|
|
||
Other
|
(9.9
|
)
|
|
4.6
|
|
||
Net cash from investing activities
|
465.4
|
|
|
(246.4
|
)
|
||
Cash Flows From Financing Activities:
|
|
|
|
||||
Issuance of external debt
|
40.0
|
|
|
36.3
|
|
||
Repayment of external debt and capital leases
|
(332.8
|
)
|
|
(177.5
|
)
|
||
Debt financing costs
|
(13.0
|
)
|
|
—
|
|
||
Proceeds from exercise of share options
|
3.9
|
|
|
4.9
|
|
||
Repurchase of shares
|
(380.8
|
)
|
|
(326.6
|
)
|
||
Other
|
(19.5
|
)
|
|
(23.0
|
)
|
||
Net cash from financing activities
|
(702.2
|
)
|
|
(485.9
|
)
|
||
Effect of currency rate changes on cash
|
1.6
|
|
|
2.1
|
|
||
Net change in cash, cash equivalents and restricted cash
|
(12.7
|
)
|
|
(47.2
|
)
|
||
Cash, cash equivalents and restricted cash at beginning of period
|
361.1
|
|
|
588.4
|
|
||
Cash, cash equivalents and restricted cash at end of period
|
$
|
348.4
|
|
|
$
|
541.2
|
|
|
|
|
|
||||
Cash and cash equivalents at end of period
|
$
|
330.2
|
|
|
$
|
521.9
|
|
Restricted cash included in prepaid expenses and other current assets at end of period
|
—
|
|
|
0.3
|
|
||
Restricted cash included in other assets at end of period
|
18.2
|
|
|
19.0
|
|
||
Cash, cash equivalents and restricted cash at end of period
|
$
|
348.4
|
|
|
$
|
541.2
|
|
|
Ordinary Shares
|
|
Treasury Shares
|
|
Additional
Paid-In Capital
|
|
Retained Earnings
|
|
Accumulated Other Comprehensive Loss
|
|
Total
Shareholders'
Equity
|
||||||||||||||||||
|
Number
|
|
Par
Value
|
|
Number
|
|
Amount
|
|
|
||||||||||||||||||||
Balance at December 30, 2016
|
118.2
|
|
|
$
|
23.6
|
|
|
13.5
|
|
|
$
|
(919.8
|
)
|
|
$
|
5,424.0
|
|
|
$
|
529.0
|
|
|
$
|
(72.5
|
)
|
|
$
|
4,984.3
|
|
Impact of accounting standard adoptions
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(72.1
|
)
|
|
—
|
|
|
(72.1
|
)
|
||||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
462.0
|
|
|
—
|
|
|
462.0
|
|
||||||
Currency translation adjustments
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7.4
|
|
|
7.4
|
|
||||||
Change in derivatives, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.6
|
|
|
0.6
|
|
||||||
Unrecognized gain on benefit plans
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
45.9
|
|
|
45.9
|
|
||||||
Unrecognized gain on investments
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10.6
|
|
|
10.6
|
|
||||||
Share options exercised
|
0.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
||||||
Vesting of restricted shares
|
0.3
|
|
|
0.1
|
|
|
—
|
|
|
(4.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4.4
|
)
|
||||||
Share-based compensation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
31.8
|
|
|
—
|
|
|
—
|
|
|
31.8
|
|
||||||
Reissuance of treasury shares
|
—
|
|
|
—
|
|
|
—
|
|
|
3.7
|
|
|
—
|
|
|
(1.4
|
)
|
|
—
|
|
|
2.3
|
|
||||||
Repurchase of shares
|
—
|
|
|
—
|
|
|
8.0
|
|
|
(376.3
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(376.3
|
)
|
||||||
Balance at June 30, 2017
|
118.6
|
|
|
$
|
23.7
|
|
|
21.5
|
|
|
$
|
(1,296.9
|
)
|
|
$
|
5,459.7
|
|
|
$
|
917.5
|
|
|
$
|
(8.0
|
)
|
|
$
|
5,096.0
|
|
1.
|
Background and Basis of Presentation
|
•
|
Specialty Brands
includes branded medicines; and
|
•
|
Specialty Generics
includes specialty generic drugs, active pharmaceutical ingredients ("API") and external manufacturing.
|
2.
|
Recently Issued Accounting Standards
|
3.
|
Discontinued Operations and Divestitures
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
Major line items constituting income from discontinued operations
|
June 30, 2017
|
|
June 24, 2016
|
|
June 30, 2017
|
|
June 24, 2016
|
||||||||
Net sales
|
$
|
—
|
|
|
$
|
104.0
|
|
|
$
|
31.6
|
|
|
$
|
206.2
|
|
Cost of sales
|
—
|
|
|
51.5
|
|
|
15.6
|
|
|
99.2
|
|
||||
Selling, general and administrative expenses
|
—
|
|
|
23.5
|
|
|
7.8
|
|
|
45.4
|
|
||||
Restructuring charges, net
|
—
|
|
|
0.1
|
|
|
—
|
|
|
0.4
|
|
||||
Other
|
—
|
|
|
1.1
|
|
|
(0.2
|
)
|
|
1.4
|
|
||||
Income from discontinued operations
|
—
|
|
|
27.8
|
|
|
8.4
|
|
|
59.8
|
|
||||
(Loss) gain on divestiture of discontinued operations
|
(5.9
|
)
|
|
—
|
|
|
363.4
|
|
|
—
|
|
||||
(Loss) income from discontinued operations, before income taxes
|
(5.9
|
)
|
|
27.8
|
|
|
371.8
|
|
|
59.8
|
|
||||
Income tax (benefit) expense
|
(0.1
|
)
|
|
8.8
|
|
|
5.3
|
|
|
19.0
|
|
||||
(Loss) income from discontinued operations, net of income taxes
|
$
|
(5.8
|
)
|
|
$
|
19.0
|
|
|
$
|
366.5
|
|
|
$
|
40.8
|
|
|
June 30, 2017
|
|
December 30, 2016
|
||||
Carrying amounts of major classes of assets included as part of discontinued operations
|
|
|
|
||||
Accounts receivable
|
$
|
—
|
|
|
$
|
49.6
|
|
Inventories
|
—
|
|
|
20.0
|
|
||
Property, plant and equipment, net
|
—
|
|
|
188.7
|
|
||
Other current and non-current assets
|
—
|
|
|
52.6
|
|
||
Total assets classified as held for sale in the balance sheet
|
$
|
—
|
|
|
$
|
310.9
|
|
|
|
|
|
||||
Carrying amounts of major classes of liabilities included as part of discontinued operations
|
|
|
|
||||
Accounts payable
|
$
|
—
|
|
|
$
|
19.7
|
|
Other current and non-current liabilities
|
—
|
|
|
100.6
|
|
||
Total liabilities classified as held for sale in the balance sheet
|
$
|
—
|
|
|
$
|
120.3
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30, 2017
|
|
June 24, 2016
|
|
June 30, 2017
|
|
June 24, 2016
|
||||||||
Depreciation
|
$
|
—
|
|
|
$
|
5.0
|
|
|
$
|
—
|
|
|
$
|
9.8
|
|
Capital expenditures
|
—
|
|
|
1.2
|
|
|
0.3
|
|
|
3.8
|
|
4.
|
Acquisitions, License Agreements and Other Investments
|
5.
|
Restructuring and Related Charges
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
Specialty Brands
|
$
|
0.3
|
|
|
$
|
8.8
|
|
|
$
|
9.5
|
|
|
$
|
16.8
|
|
Specialty Generics
|
0.5
|
|
|
1.0
|
|
|
7.9
|
|
|
1.6
|
|
||||
Corporate
|
0.7
|
|
|
5.4
|
|
|
2.8
|
|
|
6.9
|
|
||||
Restructuring and related charges, net
|
1.5
|
|
|
15.2
|
|
|
20.2
|
|
|
25.3
|
|
||||
Less: accelerated depreciation
|
(0.9
|
)
|
|
(1.2
|
)
|
|
(2.4
|
)
|
|
(2.9
|
)
|
||||
Restructuring charges, net
|
$
|
0.6
|
|
|
$
|
14.0
|
|
|
$
|
17.8
|
|
|
$
|
22.4
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
2016 Mallinckrodt Program
|
$
|
1.5
|
|
|
$
|
—
|
|
|
$
|
20.2
|
|
|
$
|
—
|
|
2013 Mallinckrodt Program
|
—
|
|
|
14.3
|
|
|
—
|
|
|
22.4
|
|
||||
Acquisitions
|
—
|
|
|
0.9
|
|
|
—
|
|
|
2.9
|
|
||||
Total
|
1.5
|
|
|
15.2
|
|
|
20.2
|
|
|
25.3
|
|
||||
Less: non-cash charges, including accelerated share-based compensation expense
|
(0.9
|
)
|
|
(1.2
|
)
|
|
(2.4
|
)
|
|
(2.9
|
)
|
||||
Total charges expected to be settled in cash
|
$
|
0.6
|
|
|
$
|
14.0
|
|
|
$
|
17.8
|
|
|
$
|
22.4
|
|
|
2016 Mallinckrodt Program
|
|
2013 Mallinckrodt Program
|
|
Acquisitions
|
|
Total
|
||||||||
Balance at December 30, 2016
|
$
|
9.5
|
|
|
$
|
5.1
|
|
|
$
|
0.2
|
|
|
$
|
14.8
|
|
Charges
|
18.5
|
|
|
—
|
|
|
—
|
|
|
18.5
|
|
||||
Changes in estimate
|
(0.7
|
)
|
|
—
|
|
|
—
|
|
|
(0.7
|
)
|
||||
Cash payments
|
(14.4
|
)
|
|
(3.6
|
)
|
|
(0.2
|
)
|
|
(18.2
|
)
|
||||
Reclassifications
|
(0.3
|
)
|
|
0.3
|
|
|
—
|
|
|
—
|
|
||||
Balance at June 30, 2017
|
$
|
12.6
|
|
|
$
|
1.8
|
|
|
$
|
—
|
|
|
$
|
14.4
|
|
|
2016 Mallinckrodt Program
|
||
Specialty Brands
|
$
|
16.7
|
|
Specialty Generics
|
9.2
|
|
|
Corporate
|
7.8
|
|
|
|
$
|
33.7
|
|
6.
|
Income Taxes
|
7.
|
Earnings per Share
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||
|
June 30, 2017
|
|
June 24, 2016
|
|
June 30, 2017
|
|
June 24, 2016
|
||||
Basic
|
98.5
|
|
|
108.6
|
|
|
100.9
|
|
|
109.9
|
|
Dilutive impact of restricted share units and share options
|
0.2
|
|
|
0.8
|
|
|
0.3
|
|
|
0.9
|
|
Diluted
|
98.7
|
|
|
109.4
|
|
|
101.2
|
|
|
110.8
|
|
8.
|
Inventories
|
|
June 30,
2017 |
|
December 30,
2016 |
||||
Raw materials and supplies
|
$
|
72.5
|
|
|
$
|
72.6
|
|
Work in process
|
170.6
|
|
|
178.4
|
|
||
Finished goods
|
96.3
|
|
|
99.7
|
|
||
|
$
|
339.4
|
|
|
$
|
350.7
|
|
9.
|
Property, Plant and Equipment
|
|
June 30,
2017 |
|
December 30, 2016
|
||||
Property, plant and equipment, gross
|
$
|
1,786.6
|
|
|
$
|
1,679.4
|
|
Less: accumulated depreciation
|
(845.9
|
)
|
|
(797.9
|
)
|
||
Property, plant and equipment, net
|
$
|
940.7
|
|
|
$
|
881.5
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30, 2017
|
|
June 24, 2016
|
|
June 30, 2017
|
|
June 24, 2016
|
||||||||
Depreciation expense
|
$
|
27.4
|
|
|
$
|
28.3
|
|
|
$
|
56.2
|
|
|
$
|
60.3
|
|
10.
|
Goodwill and Intangible Assets
|
|
June 30, 2017
|
|
December 30, 2016
|
||||||||||||
|
Gross Carrying Amount
|
|
Accumulated Impairment
|
|
Gross Carrying Amount
|
|
Accumulated Impairment
|
||||||||
Specialty Brands
|
$
|
3,446.2
|
|
|
$
|
—
|
|
|
$
|
3,498.1
|
|
|
$
|
—
|
|
Specialty Generics
|
207.0
|
|
|
(207.0
|
)
|
|
207.0
|
|
|
(207.0
|
)
|
||||
Total
|
$
|
3,653.2
|
|
|
$
|
(207.0
|
)
|
|
$
|
3,705.1
|
|
|
$
|
(207.0
|
)
|
|
June 30, 2017
|
|
December 30, 2016
|
||||||||||||
|
Gross Carrying Amount
|
|
Accumulated Impairment
|
|
Gross Carrying Amount
|
|
Accumulated Impairment
|
||||||||
Amortizable:
|
|
|
|
|
|
|
|
||||||||
Completed technology
|
$
|
9,955.6
|
|
|
$
|
1,932.1
|
|
|
$
|
10,028.7
|
|
|
$
|
1,617.1
|
|
Licenses
|
177.1
|
|
|
118.4
|
|
|
177.1
|
|
|
112.7
|
|
||||
Customer relationships
|
28.7
|
|
|
10.4
|
|
|
27.6
|
|
|
8.4
|
|
||||
Trademarks
|
82.0
|
|
|
12.6
|
|
|
82.1
|
|
|
10.9
|
|
||||
Other
|
8.6
|
|
|
7.9
|
|
|
6.7
|
|
|
6.7
|
|
||||
Total
|
$
|
10,252.0
|
|
|
$
|
2,081.4
|
|
|
$
|
10,322.2
|
|
|
$
|
1,755.8
|
|
Non-Amortizable:
|
|
|
|
|
|
|
|
||||||||
Trademarks
|
$
|
35.0
|
|
|
|
|
$
|
35.0
|
|
|
|
||||
In-process research and development
|
399.1
|
|
|
|
|
399.1
|
|
|
|
||||||
Total
|
$
|
434.1
|
|
|
|
|
$
|
434.1
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30, 2017
|
|
June 24, 2016
|
|
June 30, 2017
|
|
June 24, 2016
|
||||||||
Amortization expense
|
$
|
174.7
|
|
|
$
|
175.8
|
|
|
$
|
349.8
|
|
|
$
|
350.8
|
|
Remainder of Fiscal 2017
|
$
|
344.9
|
|
Fiscal 2018
|
686.5
|
|
|
Fiscal 2019
|
686.2
|
|
|
Fiscal 2020
|
685.9
|
|
|
Fiscal 2021
|
685.7
|
|
11.
|
Debt
|
|
June 30, 2017
|
|
December 30, 2016
|
||||||||||||
|
Principal
|
|
Unamortized Discount and Debt Issuance Costs
|
|
Principal
|
|
Unamortized Discount and Debt Issuance Costs
|
||||||||
Current maturities of long-term debt:
|
|
|
|
|
|
|
|
||||||||
Variable-rate receivable securitization
|
$
|
200.0
|
|
|
$
|
0.1
|
|
|
$
|
250.0
|
|
|
$
|
0.3
|
|
3.50% notes due April 2018
|
300.0
|
|
|
0.5
|
|
|
—
|
|
|
—
|
|
||||
Term loan due March 2021
|
—
|
|
|
—
|
|
|
20.0
|
|
|
0.3
|
|
||||
4.00% term loan due February 2022
|
1.1
|
|
|
—
|
|
|
1.0
|
|
|
—
|
|
||||
Term loan due September 2024
|
18.7
|
|
|
0.3
|
|
|
—
|
|
|
—
|
|
||||
Capital lease obligation and vendor financing agreements
|
0.5
|
|
|
—
|
|
|
0.8
|
|
|
—
|
|
||||
Total current debt
|
520.3
|
|
|
0.9
|
|
|
271.8
|
|
|
0.6
|
|
||||
Long-term debt:
|
|
|
|
|
|
|
|
||||||||
3.50% notes due April 2018
|
—
|
|
|
—
|
|
|
300.0
|
|
|
0.9
|
|
||||
4.875% notes due April 2020
|
700.0
|
|
|
7.0
|
|
|
700.0
|
|
|
8.2
|
|
||||
Term loan due March 2021
|
—
|
|
|
—
|
|
|
1,928.5
|
|
|
33.4
|
|
||||
4.00% term loan due February 2022
|
5.2
|
|
|
—
|
|
|
5.5
|
|
|
—
|
|
||||
9.50% debentures due May 2022
|
10.4
|
|
|
—
|
|
|
10.4
|
|
|
—
|
|
||||
5.75% notes due August 2022
|
884.0
|
|
|
10.5
|
|
|
884.0
|
|
|
11.6
|
|
||||
8.00% debentures due March 2023
|
4.4
|
|
|
—
|
|
|
4.4
|
|
|
—
|
|
||||
4.75% notes due April 2023
|
541.5
|
|
|
5.1
|
|
|
600.0
|
|
|
6.1
|
|
||||
5.625% notes due October 2023
|
738.0
|
|
|
10.5
|
|
|
738.0
|
|
|
11.4
|
|
||||
Term loan due September 2024
|
1,841.7
|
|
|
29.4
|
|
|
—
|
|
|
—
|
|
||||
5.50% notes due April 2025
|
692.1
|
|
|
9.6
|
|
|
695.0
|
|
|
10.2
|
|
||||
Revolving credit facility
|
—
|
|
|
6.7
|
|
|
100.0
|
|
|
3.2
|
|
||||
Total long-term debt
|
5,417.3
|
|
|
78.8
|
|
|
5,965.8
|
|
|
85.0
|
|
||||
Total debt
|
$
|
5,937.6
|
|
|
$
|
79.7
|
|
|
$
|
6,237.6
|
|
|
$
|
85.6
|
|
12.
|
Retirement Plans
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
Service cost
|
$
|
0.2
|
|
|
$
|
0.4
|
|
|
$
|
1.5
|
|
|
$
|
0.8
|
|
Interest cost
|
0.4
|
|
|
3.5
|
|
|
2.1
|
|
|
7.0
|
|
||||
Expected return on plan assets
|
—
|
|
|
(4.2
|
)
|
|
(1.3
|
)
|
|
(8.4
|
)
|
||||
Amortization of net actuarial loss
|
0.4
|
|
|
2.6
|
|
|
2.6
|
|
|
5.2
|
|
||||
Amortization of prior service cost
|
0.1
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
||||
Plan settlements
|
0.5
|
|
|
3.3
|
|
|
69.7
|
|
|
7.0
|
|
||||
Net periodic benefit cost
|
$
|
1.6
|
|
|
$
|
5.6
|
|
|
$
|
74.8
|
|
|
$
|
11.6
|
|
13.
|
Accumulated Other Comprehensive Income
|
|
Currency Translation
|
|
Unrecognized Gain (Loss) on Derivatives
|
|
Unrecognized Gain (Loss) on Benefit Plans
|
|
Unrecognized Gain on Equity Securities
|
|
Accumulated Other Comprehensive Income (Loss)
|
||||||||||
Balance at December 30, 2016
|
$
|
(19.5
|
)
|
|
$
|
(5.7
|
)
|
|
$
|
(47.3
|
)
|
|
$
|
—
|
|
|
$
|
(72.5
|
)
|
Other comprehensive income before reclassifications
|
12.1
|
|
|
—
|
|
|
5.5
|
|
|
10.6
|
|
|
28.2
|
|
|||||
Amounts reclassified from accumulated other comprehensive income
|
(4.7
|
)
|
|
0.6
|
|
|
40.4
|
|
|
—
|
|
|
36.3
|
|
|||||
Net current period other comprehensive income
|
7.4
|
|
|
0.6
|
|
|
45.9
|
|
|
10.6
|
|
|
64.5
|
|
|||||
Balance at June 30, 2017
|
$
|
(12.1
|
)
|
|
$
|
(5.1
|
)
|
|
$
|
(1.4
|
)
|
|
$
|
10.6
|
|
|
$
|
(8.0
|
)
|
|
Currency Translation
|
|
Unrecognized Gain (Loss) on Derivatives
|
|
Unrecognized Gain (Loss) on Benefit Plans
|
|
Unrecognized Gain on Equity Securities
|
|
Accumulated Other Comprehensive Income (Loss)
|
||||||||||
Balance at December 25, 2015
|
$
|
(7.9
|
)
|
|
$
|
(6.3
|
)
|
|
$
|
(51.1
|
)
|
|
$
|
—
|
|
|
$
|
(65.3
|
)
|
Other comprehensive income (loss) before reclassifications
|
8.3
|
|
|
—
|
|
|
(15.5
|
)
|
|
—
|
|
|
(7.2
|
)
|
|||||
Amounts reclassified from accumulated other comprehensive income
|
(0.7
|
)
|
|
0.4
|
|
|
7.1
|
|
|
—
|
|
|
6.8
|
|
|||||
Net current period other comprehensive income (loss)
|
7.6
|
|
|
0.4
|
|
|
(8.4
|
)
|
|
—
|
|
|
(0.4
|
)
|
|||||
Balance at June 24, 2016
|
$
|
(0.3
|
)
|
|
$
|
(5.9
|
)
|
|
$
|
(59.5
|
)
|
|
$
|
—
|
|
|
$
|
(65.7
|
)
|
|
Amount Reclassified from
Accumulated Other Comprehensive Income
|
|
|
||||||
|
Six Months Ended
|
|
|
||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Line Item in the Unaudited Condensed Consolidated
Statement of Income
|
||||
Amortization and other of unrealized loss on derivatives
|
$
|
0.8
|
|
|
$
|
0.4
|
|
|
Interest expense
|
Income tax provision
|
(0.2
|
)
|
|
—
|
|
|
Income tax benefit
|
||
Net of income taxes
|
0.6
|
|
|
0.4
|
|
|
|
||
|
|
|
|
|
|
||||
Amortization of pension and post-retirement benefit plans:
|
|
|
|
|
|
||||
Net actuarial loss
|
2.6
|
|
|
5.3
|
|
|
(1)
|
||
Prior service credit
|
(1.1
|
)
|
|
(1.4
|
)
|
|
(1)
|
||
Divestiture of discontinued operations
|
(3.1
|
)
|
|
—
|
|
|
Income from discontinued operations, net of income taxes
|
||
Plan settlements
|
69.7
|
|
|
7.0
|
|
|
(1)
Selling, general and
administrative expenses
|
||
Total before tax
|
68.1
|
|
|
10.9
|
|
|
|
||
Income tax provision
|
(27.7
|
)
|
|
(3.8
|
)
|
|
Income tax benefit
|
||
Net of income taxes
|
40.4
|
|
|
7.1
|
|
|
|
||
|
|
|
|
|
|
||||
Currency translation
|
(4.7
|
)
|
|
(0.7
|
)
|
|
Income from discontinued operations, net of income taxes
|
||
|
|
|
|
|
|
||||
Total reclassifications for the period
|
$
|
36.3
|
|
|
$
|
6.8
|
|
|
|
(1)
|
These accumulated other comprehensive income components are included in the computation of net periodic benefit cost. See Note
12
for additional details.
|
14.
|
Equity
|
|
March 2017 Repurchase Program
|
|
March 2016
Repurchase Program
|
|
November 2015 Repurchase Program
|
|||||||||||||||
|
Number of Shares
|
|
Amount
|
|
Number of Shares
|
|
Amount
|
|
Number of Shares
|
|
Amount
|
|||||||||
Authorized repurchase amount
|
|
|
$
|
1,000.0
|
|
|
|
|
$
|
350.0
|
|
|
|
|
$
|
500.0
|
|
|||
Repurchases:
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Fiscal 2016
(1)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,510,824
|
|
|
425.6
|
|
|||
Transition Period 2016
|
—
|
|
|
—
|
|
|
1,501,676
|
|
|
84.0
|
|
|
1,063,337
|
|
|
74.4
|
|
|||
Fiscal 2017
|
2,594,703
|
|
|
110.3
|
|
|
5,366,741
|
|
|
266.0
|
|
|
—
|
|
|
—
|
|
|||
Remaining amount available
|
|
|
$
|
889.7
|
|
|
|
|
$
|
—
|
|
|
|
|
$
|
—
|
|
(1)
|
Represents the Company's historical fiscal year ending on the last Friday in September.
|
15.
|
Guarantees
|
16.
|
Commitments and Contingencies
|
17.
|
Financial Instruments and Fair Value Measurements
|
|
June 30,
2017 |
|
Quoted Prices in Active Markets for Identical Assets
(Level 1)
|
|
Significant Other Observable Inputs
(Level 2)
|
|
Significant Unobservable Inputs
(Level 3)
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|||||||
Debt and equity securities held in rabbi trusts
|
$
|
32.6
|
|
|
$
|
21.5
|
|
|
$
|
11.1
|
|
|
$
|
—
|
|
Equity securities
|
31.9
|
|
|
31.9
|
|
|
—
|
|
|
—
|
|
||||
Foreign exchange forward and option contracts
|
0.6
|
|
|
0.6
|
|
|
—
|
|
|
—
|
|
||||
|
$
|
65.1
|
|
|
$
|
54.0
|
|
|
$
|
11.1
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Deferred compensation liabilities
|
$
|
35.1
|
|
|
$
|
—
|
|
|
$
|
35.1
|
|
|
$
|
—
|
|
Contingent consideration and acquired contingent liabilities
|
228.4
|
|
|
—
|
|
|
—
|
|
|
228.4
|
|
||||
Foreign exchange forward and option contracts
|
0.3
|
|
|
0.3
|
|
|
—
|
|
|
—
|
|
||||
|
$
|
263.8
|
|
|
$
|
0.3
|
|
|
$
|
35.1
|
|
|
$
|
228.4
|
|
|
December 30,
2016 |
|
Quoted Prices in Active Markets for Identical Assets
(Level 1)
|
|
Significant Other Observable Inputs
(Level 2)
|
|
Significant Unobservable Inputs
(Level 3)
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Debt and equity securities held in rabbi trusts
|
$
|
33.6
|
|
|
$
|
22.8
|
|
|
$
|
10.8
|
|
|
$
|
—
|
|
Foreign exchange forward and option contracts
|
0.7
|
|
|
0.7
|
|
|
—
|
|
|
—
|
|
||||
|
$
|
34.3
|
|
|
$
|
23.5
|
|
|
$
|
10.8
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Deferred compensation liabilities
|
$
|
32.5
|
|
|
$
|
—
|
|
|
$
|
32.5
|
|
|
$
|
—
|
|
Contingent consideration and acquired contingent liabilities
|
250.5
|
|
|
—
|
|
|
—
|
|
|
250.5
|
|
||||
Foreign exchange forward and option contracts
|
3.4
|
|
|
3.4
|
|
|
—
|
|
|
—
|
|
||||
|
$
|
286.4
|
|
|
$
|
3.4
|
|
|
$
|
32.5
|
|
|
$
|
250.5
|
|
•
|
The carrying amounts of cash and cash equivalents, accounts receivable, notes receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash was equivalent to its carrying value of
$18.2 million
and
$19.1 million
as of
June 30, 2017
and
December 30, 2016
, (level 1), respectively, which was included in prepaid expenses and other current assets and other assets on the unaudited condensed consolidated balance sheets.
|
•
|
The Company received a portion of consideration for the sale of the Intrathecal business in the form of a note receivable. The fair value of the note receivable was equivalent to its carrying value of
$154.0 million
as of June 30, 2017 (level 1).
|
•
|
The Company entered into short-term investment certificates during the three months ended December 30, 2016. These certificates are carried at cost, which approximates fair value, of
$5.0 million
and
$11.1 million
at
June 30, 2017
and
December 30, 2016
, respectively (level 2). These certificates are included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets.
|
•
|
The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of
$66.9 million
and
$67.6 million
at
June 30, 2017
and
December 30, 2016
, respectively. These contracts are included in other assets on the unaudited condensed consolidated balance sheets.
|
•
|
The carrying value of the Company's revolving credit facility and variable-rate receivable securitization approximates fair value due to the short-term nature of these instruments. The carrying value of the
4.00%
term loan approximates the fair value of the instrument, as calculated using the discounted exit price, which is therefore classified as level 3. Since the quoted market prices for the Company's term loans and
8.00%
and
9.50%
debentures are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The Company's
3.50%
,
4.75%
,
4.875%
,
5.50%
,
5.625%
and
5.75%
notes are classified as level 1, as quoted prices are available in an active market for these notes. The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:
|
|
June 30, 2017
|
|
December 30, 2016
|
||||||||||||
|
Carrying
Value
|
|
Fair
Value
|
|
Carrying
Value
|
|
Fair
Value
|
||||||||
Variable-rate receivable securitization
|
$
|
200.0
|
|
|
$
|
200.0
|
|
|
$
|
250.0
|
|
|
$
|
250.0
|
|
3.50% notes due April 2018
|
300.0
|
|
|
300.0
|
|
|
300.0
|
|
|
298.7
|
|
||||
4.875% notes due April 2020
|
700.0
|
|
|
681.9
|
|
|
700.0
|
|
|
699.5
|
|
||||
Term loans due March 2021
|
—
|
|
|
—
|
|
|
1,948.5
|
|
|
1,953.2
|
|
||||
4.00% term loan due February 2022
|
6.3
|
|
|
6.3
|
|
|
6.5
|
|
|
6.5
|
|
||||
9.50% debentures due May 2022
|
10.4
|
|
|
11.5
|
|
|
10.4
|
|
|
12.0
|
|
||||
5.75% notes due August 2022
|
884.0
|
|
|
830.8
|
|
|
884.0
|
|
|
850.3
|
|
||||
8.00% debentures due March 2023
|
4.4
|
|
|
4.7
|
|
|
4.4
|
|
|
4.9
|
|
||||
4.75% notes due April 2023
|
541.5
|
|
|
461.8
|
|
|
600.0
|
|
|
520.9
|
|
||||
5.625% notes due October 2023
|
738.0
|
|
|
674.6
|
|
|
738.0
|
|
|
682.4
|
|
||||
Term loan due September 2024
|
1,860.4
|
|
|
1,855.4
|
|
|
—
|
|
|
—
|
|
||||
5.50% notes due April 2025
|
692.1
|
|
|
604.0
|
|
|
695.0
|
|
|
615.7
|
|
||||
Revolving credit facility
|
—
|
|
|
—
|
|
|
100.0
|
|
|
100.0
|
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||
CuraScript, Inc.
|
43
|
%
|
|
38
|
%
|
|
39
|
%
|
|
36
|
%
|
McKesson Corporation
|
8
|
%
|
|
7
|
%
|
|
9
|
%
|
|
10
|
%
|
|
June 30,
2017 |
|
December 30,
2016 |
||
McKesson Corporation
|
26
|
%
|
|
28
|
%
|
Amerisource Bergen Corporation
|
15
|
%
|
|
15
|
%
|
CuraScript, Inc.
|
18
|
%
|
|
15
|
%
|
Cardinal Health, Inc.
|
9
|
%
|
|
10
|
%
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||
Acthar
|
39
|
%
|
|
34
|
%
|
|
36
|
%
|
|
33
|
%
|
Inomax
|
15
|
%
|
|
14
|
%
|
|
16
|
%
|
|
14
|
%
|
18.
|
Segment Data
|
•
|
Specialty Brands
includes branded medicines; and
|
•
|
Specialty Generics
includes specialty generic drugs, API and external manufacturing.
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
Net sales:
|
|
|
|
|
|
|
|
||||||||
Specialty Brands
|
$
|
594.5
|
|
|
$
|
589.3
|
|
|
$
|
1,151.7
|
|
|
$
|
1,124.3
|
|
Specialty Generics
|
216.0
|
|
|
263.4
|
|
|
454.6
|
|
|
527.8
|
|
||||
Net sales of reportable segments
|
810.5
|
|
|
852.7
|
|
|
1,606.3
|
|
|
1,652.1
|
|
||||
Other
(1)
|
14.0
|
|
|
13.9
|
|
|
29.1
|
|
|
30.3
|
|
||||
Net sales
|
$
|
824.5
|
|
|
$
|
866.6
|
|
|
$
|
1,635.4
|
|
|
$
|
1,682.4
|
|
Operating income:
|
|
|
|
|
|
|
|
||||||||
Specialty Brands
|
$
|
274.1
|
|
|
$
|
302.1
|
|
|
$
|
549.1
|
|
|
$
|
563.0
|
|
Specialty Generics
|
63.3
|
|
|
98.1
|
|
|
139.5
|
|
|
197.0
|
|
||||
Segment operating income
|
337.4
|
|
|
400.2
|
|
|
688.6
|
|
|
760.0
|
|
||||
Unallocated amounts:
|
|
|
|
|
|
|
|
|
|
||||||
Corporate and unallocated expenses
(2)
|
(49.1
|
)
|
|
(34.1
|
)
|
|
(116.3
|
)
|
|
(59.5
|
)
|
||||
Intangible asset amortization
|
(174.7
|
)
|
|
(175.8
|
)
|
|
(349.8
|
)
|
|
(350.8
|
)
|
||||
Restructuring and related charges, net
(3)
|
(1.5
|
)
|
|
(15.2
|
)
|
|
(20.2
|
)
|
|
(25.3
|
)
|
||||
Non-restructuring impairment charges
|
—
|
|
|
—
|
|
|
—
|
|
|
(16.9
|
)
|
||||
Operating income
|
$
|
112.1
|
|
|
$
|
175.1
|
|
|
$
|
202.3
|
|
|
$
|
307.5
|
|
(1)
|
Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.
|
(2)
|
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
|
(3)
|
Includes restructuring-related accelerated depreciation.
|
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
June 30,
2017 |
|
June 24,
2016 |
||||||||
Acthar
|
$
|
319.4
|
|
|
$
|
298.3
|
|
|
$
|
591.2
|
|
|
$
|
546.7
|
|
Inomax
|
125.5
|
|
|
121.1
|
|
|
253.9
|
|
|
236.6
|
|
||||
Ofirmev
|
75.7
|
|
|
70.7
|
|
|
149.1
|
|
|
141.8
|
|
||||
Therakos immunotherapy
|
51.2
|
|
|
52.5
|
|
|
102.4
|
|
|
102.7
|
|
||||
Hemostasis products
|
13.5
|
|
|
13.9
|
|
|
26.6
|
|
|
25.3
|
|
||||
Other
|
9.2
|
|
|
32.8
|
|
|
28.5
|
|
|
71.2
|
|
||||
Specialty Brands
|
594.5
|
|
|
589.3
|
|
|
1,151.7
|
|
|
1,124.3
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Hydrocodone (API) and hydrocodone-containing tablets
|
23.0
|
|
|
38.2
|
|
|
53.3
|
|
|
79.0
|
|
||||
Oxycodone (API) and oxycodone-containing tablets
|
25.1
|
|
|
30.6
|
|
|
47.2
|
|
|
68.5
|
|
||||
Methylphenidate ER
|
20.2
|
|
|
24.3
|
|
|
43.9
|
|
|
48.9
|
|
||||
Other controlled substances
|
107.7
|
|
|
124.7
|
|
|
215.1
|
|
|
246.6
|
|
||||
Other products
|
40.0
|
|
|
45.6
|
|
|
95.1
|
|
|
84.8
|
|
||||
Specialty Generics
|
216.0
|
|
|
263.4
|
|
|
454.6
|
|
|
527.8
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Other
(1)
|
14.0
|
|
|
13.9
|
|
|
29.1
|
|
|
30.3
|
|
||||
Net sales
|
$
|
824.5
|
|
|
$
|
866.6
|
|
|
$
|
1,635.4
|
|
|
$
|
1,682.4
|
|
(1)
|
Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.
|
19.
|
Condensed Consolidating Financial Statements
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
||||||||||
Current Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
|
$
|
0.9
|
|
|
$
|
149.9
|
|
|
$
|
179.4
|
|
|
$
|
—
|
|
|
$
|
330.2
|
|
Accounts receivable, net
|
—
|
|
|
—
|
|
|
482.1
|
|
|
—
|
|
|
482.1
|
|
|||||
Inventories
|
—
|
|
|
—
|
|
|
339.4
|
|
|
—
|
|
|
339.4
|
|
|||||
Prepaid expenses and other current assets
|
0.4
|
|
|
0.4
|
|
|
133.2
|
|
|
—
|
|
|
134.0
|
|
|||||
Notes receivable
|
—
|
|
|
—
|
|
|
154.0
|
|
|
—
|
|
|
154.0
|
|
|||||
Current assets held for sale
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Intercompany receivables
|
95.7
|
|
|
19.7
|
|
|
1,135.7
|
|
|
(1,251.1
|
)
|
|
—
|
|
|||||
Total current assets
|
97.0
|
|
|
170.0
|
|
|
2,423.8
|
|
|
(1,251.1
|
)
|
|
1,439.7
|
|
|||||
Property, plant and equipment, net
|
—
|
|
|
—
|
|
|
940.7
|
|
|
—
|
|
|
940.7
|
|
|||||
Goodwill
|
—
|
|
|
—
|
|
|
3,446.2
|
|
|
—
|
|
|
3,446.2
|
|
|||||
Intangible assets, net
|
—
|
|
|
—
|
|
|
8,604.7
|
|
|
—
|
|
|
8,604.7
|
|
|||||
Investment in subsidiaries
|
4,846.2
|
|
|
21,498.0
|
|
|
10,484.6
|
|
|
(36,828.8
|
)
|
|
—
|
|
|||||
Intercompany loans receivable
|
805.2
|
|
|
—
|
|
|
4,203.7
|
|
|
(5,008.9
|
)
|
|
—
|
|
|||||
Other assets
|
—
|
|
|
—
|
|
|
189.9
|
|
|
—
|
|
|
189.9
|
|
|||||
Total Assets
|
$
|
5,748.4
|
|
|
$
|
21,668.0
|
|
|
$
|
30,293.6
|
|
|
$
|
(43,088.8
|
)
|
|
$
|
14,621.2
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Liabilities and Shareholders' Equity
|
|
|
|
|
|
|
|
|
|
||||||||||
Current Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Current maturities of long-term debt
|
$
|
—
|
|
|
$
|
317.8
|
|
|
$
|
201.6
|
|
|
$
|
—
|
|
|
$
|
519.4
|
|
Accounts payable
|
0.1
|
|
|
0.9
|
|
|
112.9
|
|
|
—
|
|
|
113.9
|
|
|||||
Accrued payroll and payroll-related costs
|
—
|
|
|
—
|
|
|
92.8
|
|
|
—
|
|
|
92.8
|
|
|||||
Accrued interest
|
—
|
|
|
53.0
|
|
|
1.1
|
|
|
—
|
|
|
54.1
|
|
|||||
Income taxes payable
|
—
|
|
|
—
|
|
|
122.0
|
|
|
—
|
|
|
122.0
|
|
|||||
Accrued and other current liabilities
|
0.5
|
|
|
0.4
|
|
|
459.3
|
|
|
—
|
|
|
460.2
|
|
|||||
Current liabilities held for sale
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Intercompany payables
|
651.8
|
|
|
476.3
|
|
|
123.0
|
|
|
(1,251.1
|
)
|
|
—
|
|
|||||
Total current liabilities
|
652.4
|
|
|
848.4
|
|
|
1,112.7
|
|
|
(1,251.1
|
)
|
|
1,362.4
|
|
|||||
Long-term debt
|
—
|
|
|
5,318.6
|
|
|
19.9
|
|
|
—
|
|
|
5,338.5
|
|
|||||
Pension and postretirement benefits
|
—
|
|
|
—
|
|
|
67.7
|
|
|
—
|
|
|
67.7
|
|
|||||
Environmental liabilities
|
—
|
|
|
—
|
|
|
73.6
|
|
|
—
|
|
|
73.6
|
|
|||||
Deferred income taxes
|
—
|
|
|
—
|
|
|
2,254.4
|
|
|
—
|
|
|
2,254.4
|
|
|||||
Other income tax liabilities
|
—
|
|
|
—
|
|
|
67.5
|
|
|
—
|
|
|
67.5
|
|
|||||
Intercompany loans payable
|
—
|
|
|
5,008.9
|
|
|
—
|
|
|
(5,008.9
|
)
|
|
—
|
|
|||||
Other liabilities
|
—
|
|
|
7.5
|
|
|
353.6
|
|
|
—
|
|
|
361.1
|
|
|||||
Total Liabilities
|
652.4
|
|
|
11,183.4
|
|
|
3,949.4
|
|
|
(6,260.0
|
)
|
|
9,525.2
|
|
|||||
Shareholders' Equity
|
5,096.0
|
|
|
10,484.6
|
|
|
26,344.2
|
|
|
(36,828.8
|
)
|
|
5,096.0
|
|
|||||
Total Liabilities and Shareholders' Equity
|
$
|
5,748.4
|
|
|
$
|
21,668.0
|
|
|
$
|
30,293.6
|
|
|
$
|
(43,088.8
|
)
|
|
$
|
14,621.2
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Assets
|
|
|
|
|
|
|
|
|
|
||||||||||
Current Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
|
$
|
0.5
|
|
|
$
|
44.5
|
|
|
$
|
297.0
|
|
|
$
|
—
|
|
|
$
|
342.0
|
|
Accounts receivable, net
|
—
|
|
|
—
|
|
|
431.0
|
|
|
—
|
|
|
431.0
|
|
|||||
Inventories
|
—
|
|
|
—
|
|
|
350.7
|
|
|
—
|
|
|
350.7
|
|
|||||
Prepaid expenses and other current assets
|
1.0
|
|
|
—
|
|
|
130.9
|
|
|
—
|
|
|
131.9
|
|
|||||
Notes receivable
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Current assets held for sale
|
—
|
|
|
—
|
|
|
310.9
|
|
|
—
|
|
|
310.9
|
|
|||||
Intercompany receivables
|
59.7
|
|
|
65.1
|
|
|
1,081.3
|
|
|
(1,206.1
|
)
|
|
—
|
|
|||||
Total current assets
|
61.2
|
|
|
109.6
|
|
|
2,601.8
|
|
|
(1,206.1
|
)
|
|
1,566.5
|
|
|||||
Property, plant and equipment, net
|
—
|
|
|
—
|
|
|
881.5
|
|
|
—
|
|
|
881.5
|
|
|||||
Goodwill
|
—
|
|
|
—
|
|
|
3,498.1
|
|
|
—
|
|
|
3,498.1
|
|
|||||
Intangible assets, net
|
—
|
|
|
—
|
|
|
9,000.5
|
|
|
—
|
|
|
9,000.5
|
|
|||||
Investment in subsidiaries
|
5,534.1
|
|
|
20,624.1
|
|
|
10,988.5
|
|
|
(37,146.7
|
)
|
|
—
|
|
|||||
Intercompany loans receivable
|
3.5
|
|
|
—
|
|
|
3,325.9
|
|
|
(3,329.4
|
)
|
|
—
|
|
|||||
Other assets
|
—
|
|
|
—
|
|
|
259.7
|
|
|
—
|
|
|
259.7
|
|
|||||
Total Assets
|
$
|
5,598.8
|
|
|
$
|
20,733.7
|
|
|
$
|
30,556.0
|
|
|
$
|
(41,682.2
|
)
|
|
$
|
15,206.3
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Liabilities and Shareholders' Equity
|
|
|
|
|
|
|
|
|
|
||||||||||
Current Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Current maturities of long-term debt
|
$
|
—
|
|
|
$
|
19.7
|
|
|
$
|
251.5
|
|
|
$
|
—
|
|
|
$
|
271.2
|
|
Accounts payable
|
0.1
|
|
|
0.1
|
|
|
111.9
|
|
|
—
|
|
|
112.1
|
|
|||||
Accrued payroll and payroll-related costs
|
—
|
|
|
—
|
|
|
76.1
|
|
|
—
|
|
|
76.1
|
|
|||||
Accrued interest
|
—
|
|
|
53.9
|
|
|
14.8
|
|
|
—
|
|
|
68.7
|
|
|||||
Income taxes payable
|
—
|
|
|
—
|
|
|
101.7
|
|
|
—
|
|
|
101.7
|
|
|||||
Accrued and other current liabilities
|
1.9
|
|
|
7.5
|
|
|
547.7
|
|
|
—
|
|
|
557.1
|
|
|||||
Current liabilities held for sale
|
—
|
|
|
—
|
|
|
120.3
|
|
|
—
|
|
|
120.3
|
|
|||||
Intercompany payables
|
612.5
|
|
|
467.1
|
|
|
126.5
|
|
|
(1,206.1
|
)
|
|
—
|
|
|||||
Total current liabilities
|
614.5
|
|
|
548.3
|
|
|
1,350.5
|
|
|
(1,206.1
|
)
|
|
1,307.2
|
|
|||||
Long-term debt
|
—
|
|
|
5,860.6
|
|
|
20.2
|
|
|
—
|
|
|
5,880.8
|
|
|||||
Pension and postretirement benefits
|
—
|
|
|
—
|
|
|
136.4
|
|
|
—
|
|
|
136.4
|
|
|||||
Environmental liabilities
|
—
|
|
|
—
|
|
|
73.0
|
|
|
—
|
|
|
73.0
|
|
|||||
Deferred income taxes
|
—
|
|
|
—
|
|
|
2,398.1
|
|
|
—
|
|
|
2,398.1
|
|
|||||
Other income tax liabilities
|
—
|
|
|
—
|
|
|
70.4
|
|
|
—
|
|
|
70.4
|
|
|||||
Intercompany loans payable
|
—
|
|
|
3,329.4
|
|
|
—
|
|
|
(3,329.4
|
)
|
|
—
|
|
|||||
Other liabilities
|
—
|
|
|
7.0
|
|
|
349.1
|
|
|
—
|
|
|
356.1
|
|
|||||
Total Liabilities
|
614.5
|
|
|
9,745.3
|
|
|
4,397.7
|
|
|
(4,535.5
|
)
|
|
10,222.0
|
|
|||||
Shareholders' Equity
|
4,984.3
|
|
|
10,988.4
|
|
|
26,158.3
|
|
|
(37,146.7
|
)
|
|
4,984.3
|
|
|||||
Total Liabilities and Shareholders' Equity
|
$
|
5,598.8
|
|
|
$
|
20,733.7
|
|
|
$
|
30,556.0
|
|
|
$
|
(41,682.2
|
)
|
|
$
|
15,206.3
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Net sales
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
824.5
|
|
|
$
|
—
|
|
|
$
|
824.5
|
|
Cost of sales
|
0.9
|
|
|
—
|
|
|
407.5
|
|
|
—
|
|
|
408.4
|
|
|||||
Gross profit
|
(0.9
|
)
|
|
—
|
|
|
417.0
|
|
|
—
|
|
|
416.1
|
|
|||||
Selling, general and administrative expenses
|
15.1
|
|
|
0.2
|
|
|
216.8
|
|
|
—
|
|
|
232.1
|
|
|||||
Research and development expenses
|
1.8
|
|
|
—
|
|
|
67.4
|
|
|
—
|
|
|
69.2
|
|
|||||
Restructuring charges, net
|
—
|
|
|
—
|
|
|
0.6
|
|
|
—
|
|
|
0.6
|
|
|||||
Non-restructuring impairment charges
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Losses on divestiture and license
|
—
|
|
|
—
|
|
|
2.1
|
|
|
—
|
|
|
2.1
|
|
|||||
Operating income
|
(17.8
|
)
|
|
(0.2
|
)
|
|
130.1
|
|
|
—
|
|
|
112.1
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense
|
(3.4
|
)
|
|
(88.7
|
)
|
|
(18.7
|
)
|
|
18.6
|
|
|
(92.2
|
)
|
|||||
Interest income
|
2.0
|
|
|
0.3
|
|
|
16.9
|
|
|
(18.6
|
)
|
|
0.6
|
|
|||||
Other income, net
|
2.2
|
|
|
6.6
|
|
|
1.2
|
|
|
—
|
|
|
10.0
|
|
|||||
Intercompany fees
|
(3.5
|
)
|
|
—
|
|
|
3.5
|
|
|
—
|
|
|
—
|
|
|||||
Equity in net income of subsidiaries
|
81.0
|
|
|
254.7
|
|
|
172.9
|
|
|
(508.6
|
)
|
|
—
|
|
|||||
Income from continuing operations before income taxes
|
60.5
|
|
|
172.7
|
|
|
305.9
|
|
|
(508.6
|
)
|
|
30.5
|
|
|||||
Income tax benefit
|
(1.3
|
)
|
|
(0.2
|
)
|
|
(38.6
|
)
|
|
—
|
|
|
(40.1
|
)
|
|||||
Income from continuing operations
|
61.8
|
|
|
172.9
|
|
|
344.5
|
|
|
(508.6
|
)
|
|
70.6
|
|
|||||
Income (loss) from discontinued operations, net of income taxes
|
1.0
|
|
|
—
|
|
|
(8.8
|
)
|
|
—
|
|
|
(7.8
|
)
|
|||||
Net income
|
62.8
|
|
|
172.9
|
|
|
335.7
|
|
|
(508.6
|
)
|
|
62.8
|
|
|||||
Other comprehensive income, net of tax
|
1.9
|
|
|
1.9
|
|
|
3.4
|
|
|
(5.3
|
)
|
|
1.9
|
|
|||||
Comprehensive income
|
$
|
64.7
|
|
|
$
|
174.8
|
|
|
$
|
339.1
|
|
|
$
|
(513.9
|
)
|
|
$
|
64.7
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Net sales
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
866.6
|
|
|
$
|
—
|
|
|
$
|
866.6
|
|
Cost of sales
|
—
|
|
|
—
|
|
|
377.8
|
|
|
—
|
|
|
377.8
|
|
|||||
Gross profit
|
—
|
|
|
—
|
|
|
488.8
|
|
|
—
|
|
|
488.8
|
|
|||||
Selling, general and administrative expenses
|
12.3
|
|
|
0.2
|
|
|
212.4
|
|
|
—
|
|
|
224.9
|
|
|||||
Research and development expenses
|
—
|
|
|
—
|
|
|
74.8
|
|
|
—
|
|
|
74.8
|
|
|||||
Restructuring charges, net
|
—
|
|
|
—
|
|
|
14.0
|
|
|
—
|
|
|
14.0
|
|
|||||
Non-restructuring impairment charge
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Losses on divestiture and license
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Operating income
|
(12.3
|
)
|
|
(0.2
|
)
|
|
187.6
|
|
|
—
|
|
|
175.1
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense
|
(56.3
|
)
|
|
(81.6
|
)
|
|
(20.3
|
)
|
|
62.6
|
|
|
(95.6
|
)
|
|||||
Interest income
|
—
|
|
|
0.1
|
|
|
62.9
|
|
|
(62.6
|
)
|
|
0.4
|
|
|||||
Other income (expense), net
|
2.6
|
|
|
0.1
|
|
|
(4.0
|
)
|
|
—
|
|
|
(1.3
|
)
|
|||||
Intercompany fees
|
(4.5
|
)
|
|
—
|
|
|
4.5
|
|
|
—
|
|
|
—
|
|
|||||
Equity in net income of subsidiaries
|
260.2
|
|
|
380.5
|
|
|
308.9
|
|
|
(949.6
|
)
|
|
—
|
|
|||||
Income from continuing operations before income taxes
|
189.7
|
|
|
298.9
|
|
|
539.6
|
|
|
(949.6
|
)
|
|
78.6
|
|
|||||
Income tax benefit
|
(9.6
|
)
|
|
(10.2
|
)
|
|
(78.3
|
)
|
|
—
|
|
|
(98.1
|
)
|
|||||
Income from continuing operations
|
199.3
|
|
|
309.1
|
|
|
617.9
|
|
|
(949.6
|
)
|
|
176.7
|
|
|||||
(Loss) income from discontinued operations, net of income taxes
|
—
|
|
|
(0.2
|
)
|
|
22.8
|
|
|
—
|
|
|
22.6
|
|
|||||
Net income
|
199.3
|
|
|
308.9
|
|
|
640.7
|
|
|
(949.6
|
)
|
|
199.3
|
|
|||||
Other comprehensive loss, net of tax
|
(0.6
|
)
|
|
(0.6
|
)
|
|
(1.4
|
)
|
|
2.0
|
|
|
(0.6
|
)
|
|||||
Comprehensive income
|
$
|
198.7
|
|
|
$
|
308.3
|
|
|
$
|
639.3
|
|
|
$
|
(947.6
|
)
|
|
$
|
198.7
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Net sales
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,635.4
|
|
|
$
|
—
|
|
|
$
|
1,635.4
|
|
Cost of sales
|
0.9
|
|
|
—
|
|
|
799.8
|
|
|
—
|
|
|
800.7
|
|
|||||
Gross profit
|
(0.9
|
)
|
|
—
|
|
|
835.6
|
|
|
—
|
|
|
834.7
|
|
|||||
Selling, general and administrative expenses
|
33.3
|
|
|
0.4
|
|
|
506.5
|
|
|
—
|
|
|
540.2
|
|
|||||
Research and development expenses
|
1.8
|
|
|
—
|
|
|
129.6
|
|
|
—
|
|
|
131.4
|
|
|||||
Restructuring charges, net
|
—
|
|
|
—
|
|
|
17.8
|
|
|
—
|
|
|
17.8
|
|
|||||
Non-restructuring impairment charge
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Gains on divestiture and license
|
—
|
|
|
—
|
|
|
(57.0
|
)
|
|
—
|
|
|
(57.0
|
)
|
|||||
Operating income
|
(36.0
|
)
|
|
(0.4
|
)
|
|
238.7
|
|
|
—
|
|
|
202.3
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense
|
(6.7
|
)
|
|
(174.0
|
)
|
|
(38.9
|
)
|
|
33.2
|
|
|
(186.4
|
)
|
|||||
Interest income
|
3.1
|
|
|
0.6
|
|
|
31.0
|
|
|
(33.2
|
)
|
|
1.5
|
|
|||||
Other income (expense), net
|
17.6
|
|
|
(3.3
|
)
|
|
(11.8
|
)
|
|
—
|
|
|
2.5
|
|
|||||
Intercompany fees
|
(9.0
|
)
|
|
—
|
|
|
9.0
|
|
|
—
|
|
|
—
|
|
|||||
Equity in net income of subsidiaries
|
489.7
|
|
|
851.7
|
|
|
673.4
|
|
|
(2,014.8
|
)
|
|
—
|
|
|||||
Income from continuing operations before income taxes
|
458.7
|
|
|
674.6
|
|
|
901.4
|
|
|
(2,014.8
|
)
|
|
19.9
|
|
|||||
Income tax benefit
|
(3.3
|
)
|
|
(0.5
|
)
|
|
(75.8
|
)
|
|
—
|
|
|
(79.6
|
)
|
|||||
Income from continuing operations
|
462.0
|
|
|
675.1
|
|
|
977.2
|
|
|
(2,014.8
|
)
|
|
99.5
|
|
|||||
(Loss) income from discontinued operations, net of income taxes
|
—
|
|
|
(1.7
|
)
|
|
364.2
|
|
|
—
|
|
|
362.5
|
|
|||||
Net income
|
462.0
|
|
|
673.4
|
|
|
1,341.4
|
|
|
(2,014.8
|
)
|
|
462.0
|
|
|||||
Other comprehensive income, net of tax
|
64.5
|
|
|
64.5
|
|
|
128.4
|
|
|
(192.9
|
)
|
|
64.5
|
|
|||||
Comprehensive income
|
$
|
526.5
|
|
|
$
|
737.9
|
|
|
$
|
1,469.8
|
|
|
$
|
(2,207.7
|
)
|
|
$
|
526.5
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Net sales
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,682.4
|
|
|
$
|
—
|
|
|
$
|
1,682.4
|
|
Cost of sales
|
—
|
|
|
—
|
|
|
768.5
|
|
|
—
|
|
|
768.5
|
|
|||||
Gross profit
|
—
|
|
|
—
|
|
|
913.9
|
|
|
—
|
|
|
913.9
|
|
|||||
Selling, general and administrative expenses
|
26.2
|
|
|
0.4
|
|
|
407.6
|
|
|
—
|
|
|
434.2
|
|
|||||
Research and development expenses
|
—
|
|
|
—
|
|
|
132.9
|
|
|
—
|
|
|
132.9
|
|
|||||
Restructuring charges, net
|
—
|
|
|
—
|
|
|
22.4
|
|
|
—
|
|
|
22.4
|
|
|||||
Non-restructuring impairment charge
|
—
|
|
|
—
|
|
|
16.9
|
|
|
—
|
|
|
16.9
|
|
|||||
Gains on divestiture and license
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Operating income
|
(26.2
|
)
|
|
(0.4
|
)
|
|
334.1
|
|
|
—
|
|
|
307.5
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest expense
|
(126.2
|
)
|
|
(163.1
|
)
|
|
(42.0
|
)
|
|
138.5
|
|
|
(192.8
|
)
|
|||||
Interest income
|
—
|
|
|
0.3
|
|
|
138.8
|
|
|
(138.5
|
)
|
|
0.6
|
|
|||||
Other income (expense), net
|
14.9
|
|
|
—
|
|
|
(16.9
|
)
|
|
—
|
|
|
(2.0
|
)
|
|||||
Intercompany fees
|
(7.3
|
)
|
|
0.1
|
|
|
7.2
|
|
|
—
|
|
|
—
|
|
|||||
Equity in net income of subsidiaries
|
452.7
|
|
|
712.5
|
|
|
561.7
|
|
|
(1,726.9
|
)
|
|
—
|
|
|||||
Income from continuing operations before income taxes
|
307.9
|
|
|
549.4
|
|
|
982.9
|
|
|
(1,726.9
|
)
|
|
113.3
|
|
|||||
Income tax benefit
|
(9.7
|
)
|
|
(14.0
|
)
|
|
(138.2
|
)
|
|
—
|
|
|
(161.9
|
)
|
|||||
Income from continuing operations
|
317.6
|
|
|
563.4
|
|
|
1,121.1
|
|
|
(1,726.9
|
)
|
|
275.2
|
|
|||||
(Loss) income from discontinued operations, net of income taxes
|
—
|
|
|
(1.7
|
)
|
|
44.1
|
|
|
—
|
|
|
42.4
|
|
|||||
Net income
|
317.6
|
|
|
561.7
|
|
|
1,165.2
|
|
|
(1,726.9
|
)
|
|
317.6
|
|
|||||
Other comprehensive loss, net of tax
|
(0.4
|
)
|
|
(0.4
|
)
|
|
(1.2
|
)
|
|
1.6
|
|
|
(0.4
|
)
|
|||||
Comprehensive income
|
$
|
317.2
|
|
|
$
|
561.3
|
|
|
$
|
1,164.0
|
|
|
$
|
(1,725.3
|
)
|
|
$
|
317.2
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Cash Flows From Operating Activities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net cash from operating activities
|
$
|
1,177.0
|
|
|
$
|
175.8
|
|
|
$
|
1,487.0
|
|
|
$
|
(2,617.3
|
)
|
|
$
|
222.5
|
|
Cash Flows From Investing Activities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Capital expenditures
|
—
|
|
|
—
|
|
|
(101.6
|
)
|
|
—
|
|
|
(101.6
|
)
|
|||||
Acquisitions and intangibles, net of cash acquired
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Proceeds from divestiture of discontinued operations, net of cash
|
—
|
|
|
—
|
|
|
576.9
|
|
|
—
|
|
|
576.9
|
|
|||||
Intercompany loan investment, net
|
(801.7
|
)
|
|
—
|
|
|
(860.4
|
)
|
|
1,662.1
|
|
|
—
|
|
|||||
Investment in subsidiary
|
—
|
|
|
(307.9
|
)
|
|
—
|
|
|
307.9
|
|
|
—
|
|
|||||
Other
|
—
|
|
|
—
|
|
|
(9.9
|
)
|
|
—
|
|
|
(9.9
|
)
|
|||||
Net cash from investing activities
|
(801.7
|
)
|
|
(307.9
|
)
|
|
(395.0
|
)
|
|
1,970.0
|
|
|
465.4
|
|
|||||
Cash Flows From Financing Activities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Issuance of external debt
|
—
|
|
|
—
|
|
|
40.0
|
|
|
—
|
|
|
40.0
|
|
|||||
Repayment of external debt and capital leases
|
—
|
|
|
(242.1
|
)
|
|
(90.7
|
)
|
|
—
|
|
|
(332.8
|
)
|
|||||
Debt financing costs
|
—
|
|
|
(12.5
|
)
|
|
(0.5
|
)
|
|
—
|
|
|
(13.0
|
)
|
|||||
Proceeds from exercise of share options
|
3.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|||||
Repurchase of shares
|
(380.8
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(380.8
|
)
|
|||||
Intercompany loan borrowings, net
|
—
|
|
|
1,662.1
|
|
|
—
|
|
|
(1,662.1
|
)
|
|
—
|
|
|||||
Intercompany dividends
|
—
|
|
|
(1,170.0
|
)
|
|
(1,447.3
|
)
|
|
2,617.3
|
|
|
—
|
|
|||||
Capital contribution
|
—
|
|
|
—
|
|
|
307.9
|
|
|
(307.9
|
)
|
|
—
|
|
|||||
Other
|
2.0
|
|
|
—
|
|
|
(21.5
|
)
|
|
—
|
|
|
(19.5
|
)
|
|||||
Net cash from financing activities
|
(374.9
|
)
|
|
237.5
|
|
|
(1,212.1
|
)
|
|
647.3
|
|
|
(702.2
|
)
|
|||||
Effect of currency rate changes on cash
|
—
|
|
|
—
|
|
|
1.6
|
|
|
—
|
|
|
1.6
|
|
|||||
Net change in cash, cash equivalents and restricted cash
|
0.4
|
|
|
105.4
|
|
|
(118.5
|
)
|
|
—
|
|
|
(12.7
|
)
|
|||||
Cash, cash equivalents and restricted cash at beginning of period
|
0.5
|
|
|
44.5
|
|
|
316.1
|
|
|
—
|
|
|
361.1
|
|
|||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
0.9
|
|
|
$
|
149.9
|
|
|
$
|
197.6
|
|
|
$
|
—
|
|
|
$
|
348.4
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents at end of period
|
$
|
0.9
|
|
|
$
|
149.9
|
|
|
$
|
179.4
|
|
|
$
|
—
|
|
|
$
|
330.2
|
|
Restricted Cash, Current at end of period
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Restricted Cash, Noncurrent at end of period
|
—
|
|
|
—
|
|
|
18.2
|
|
|
—
|
|
|
18.2
|
|
|||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
0.9
|
|
|
$
|
149.9
|
|
|
$
|
197.6
|
|
|
$
|
—
|
|
|
$
|
348.4
|
|
|
Mallinckrodt plc
|
|
Mallinckrodt International Finance S.A.
|
|
Other Subsidiaries
|
|
Eliminations
|
|
Consolidated
|
||||||||||
Cash Flows From Operating Activities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Net cash from operating activities
|
$
|
(4.3
|
)
|
|
$
|
(72.9
|
)
|
|
$
|
760.2
|
|
|
$
|
—
|
|
|
$
|
683.0
|
|
Cash Flows From Investing Activities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Capital expenditures
|
—
|
|
|
—
|
|
|
(84.5
|
)
|
|
—
|
|
|
(84.5
|
)
|
|||||
Acquisitions and intangibles, net of cash acquired
|
—
|
|
|
—
|
|
|
(169.5
|
)
|
|
—
|
|
|
(169.5
|
)
|
|||||
Proceeds from divestiture of discontinued operations, net of cash
|
—
|
|
|
(1.4
|
)
|
|
4.4
|
|
|
—
|
|
|
3.0
|
|
|||||
Intercompany loan investment, net
|
—
|
|
|
105.8
|
|
|
(952.4
|
)
|
|
846.6
|
|
|
—
|
|
|||||
Investment in subsidiary
|
—
|
|
|
(461.7
|
)
|
|
—
|
|
|
461.7
|
|
|
—
|
|
|||||
Other
|
—
|
|
|
—
|
|
|
4.6
|
|
|
—
|
|
|
4.6
|
|
|||||
Net cash from investing activities
|
—
|
|
|
(357.3
|
)
|
|
(1,197.4
|
)
|
|
1,308.3
|
|
|
(246.4
|
)
|
|||||
Cash Flows From Financing Activities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Issuance of external debt
|
—
|
|
|
—
|
|
|
36.3
|
|
|
—
|
|
|
36.3
|
|
|||||
Repayment of external debt and capital leases
|
—
|
|
|
(160.3
|
)
|
|
(17.2
|
)
|
|
—
|
|
|
(177.5
|
)
|
|||||
Debt financing costs
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
Proceeds from exercise of share options
|
4.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
4.9
|
|
|||||
Repurchase of shares
|
(326.6
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(326.6
|
)
|
|||||
Intercompany loan borrowings, net
|
325.8
|
|
|
520.8
|
|
|
—
|
|
|
(846.6
|
)
|
|
—
|
|
|||||
Capital contribution
|
—
|
|
|
—
|
|
|
461.7
|
|
|
(461.7
|
)
|
|
—
|
|
|||||
Other
|
—
|
|
|
—
|
|
|
(23.0
|
)
|
|
—
|
|
|
(23.0
|
)
|
|||||
Net cash from financing activities
|
4.1
|
|
|
360.5
|
|
|
457.8
|
|
|
(1,308.3
|
)
|
|
(485.9
|
)
|
|||||
Effect of currency rate changes on cash
|
—
|
|
|
—
|
|
|
2.1
|
|
|
—
|
|
|
2.1
|
|
|||||
Net change in cash, cash equivalents and restricted cash
|
(0.2
|
)
|
|
(69.7
|
)
|
|
22.7
|
|
|
—
|
|
|
(47.2
|
)
|
|||||
Cash, cash equivalents and restricted cash at beginning of period
|
0.3
|
|
|
158.5
|
|
|
429.6
|
|
|
—
|
|
|
588.4
|
|
|||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
0.1
|
|
|
$
|
88.8
|
|
|
$
|
452.3
|
|
|
$
|
—
|
|
|
$
|
541.2
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents at end of period
|
$
|
0.1
|
|
|
$
|
88.8
|
|
|
$
|
433.0
|
|
|
$
|
—
|
|
|
$
|
521.9
|
|
Restricted Cash, Current at end of period
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
0.3
|
|
|||||
Restricted Cash, Noncurrent at end of period
|
—
|
|
|
—
|
|
|
19.0
|
|
|
—
|
|
|
19.0
|
|
|||||
Cash, cash equivalents and restricted cash at end of period
|
$
|
0.1
|
|
|
$
|
88.8
|
|
|
$
|
452.3
|
|
|
$
|
—
|
|
|
$
|
541.2
|
|
20.
|
Subsequent Events
|
Item 2.
|
Management's Discussion and Analysis of Financial Condition and Results of Operations.
|
•
|
Specialty Brands
includes branded medicines; and
|
•
|
Specialty Generics
includes specialty generic drugs, active pharmaceutical ingredients ("API") and external manufacturing.
|
•
|
Terlipressin is being investigated for the treatment of Hepatorenal Syndrome ("HRS") type 1, an acute, rare and life-threatening condition requiring hospitalization, with no currently approved therapy in the U.S. or Canada. In July 2016, we enrolled the first patient in our Phase 3 clinical study to evaluate the efficacy and safety of terlipressin (for injection) in subjects with HRS type 1. In July 2017, we announced the enrollment of the 75th subject in our ongoing Phase 3 clinical study, achieving one quarter of our target enrollment for this trial.
|
•
|
StrataGraft is an investigational product in Phase 3 development for treatment of severe, deep partial thickness burns and Phase 2 development for treatment of severe, full thickness burns. In 2012, the FDA granted StrataGraft orphan product status, and the product is being developed as a biologic to be filed under a biologic license application that would confer regulatory protection until 2032. In June 2017, we announced the enrollment of the first patient in our Phase 3 clinical study to evaluate the efficacy and safety of StrataGraft regenerative skin tissue in the promotion of autologous skin regeneration of complex skin defects due to thermal burns that contain intact dermal elements. In July 2017, we announced that StrataGraft is among the first products to be designated as a Regenerative Medicine Advanced Therapy ("RMAT") by the FDA under the provisions of the 21st Century Cures Act. The RMAT designation allows for earlier and increased interactions with the FDA, including discussions of whether priority review and/or accelerated approval would be appropriate based on surrogate or intermediate endpoints that would be reasonably likely to predict long-term clinical benefit; or reliance upon data obtained from a meaningful number of sites.
|
•
|
MNK-1411 (the product formerly described as Synacthen Depot®) is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. In August 2016, we announced that the FDA has granted our request for fast track designation for its Investigational New Drug ("IND") application for MNK-1411 in the treatment of Duchenne muscular dystrophy ("DMD"). The FDA's fast track designation is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions that fill an unmet medical need. We completed a Phase 1 study for MNK-1411 in healthy volunteers, and are using the information that was derived to determine optimal dosing in our Phase 2 trial, which is expected to commence during the second half of 2017. In July 2017, we announced that the FDA had granted orphan drug designation to MNK-1411 for the treatment of DMD.
|
|
Three Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change |
|||||
U.S.
|
$
|
751.0
|
|
|
$
|
796.7
|
|
|
(5.7
|
)%
|
Europe, Middle East and Africa
|
56.7
|
|
|
54.8
|
|
|
3.5
|
|
||
Other
|
16.8
|
|
|
15.1
|
|
|
11.3
|
|
||
Net sales
|
$
|
824.5
|
|
|
$
|
866.6
|
|
|
(4.9
|
)
|
|
Six Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change |
|||||
U.S.
|
$
|
1,486.7
|
|
|
$
|
1,541.1
|
|
|
(3.5
|
)%
|
Europe, Middle East and Africa
|
115.9
|
|
|
108.1
|
|
|
7.2
|
|
||
Other
|
32.8
|
|
|
33.2
|
|
|
(1.2
|
)
|
||
Net sales
|
$
|
1,635.4
|
|
|
$
|
1,682.4
|
|
|
(2.8
|
)
|
|
Three Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change
|
|||||
Specialty Brands
|
$
|
594.5
|
|
|
$
|
589.3
|
|
|
0.9
|
%
|
Specialty Generics
|
216.0
|
|
|
263.4
|
|
|
(18.0
|
)
|
||
Net sales of operating segments
|
810.5
|
|
|
852.7
|
|
|
(4.9
|
)
|
||
Other
(1)
|
14.0
|
|
|
13.9
|
|
|
0.7
|
|
||
Net sales
|
$
|
824.5
|
|
|
$
|
866.6
|
|
|
(4.9
|
)
|
(1)
|
Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business.
|
|
Three Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change |
|||||
U.S.
|
$
|
575.0
|
|
|
$
|
569.3
|
|
|
1.0
|
%
|
Europe, Middle East and Africa
|
17.8
|
|
|
18.4
|
|
|
(3.3
|
)
|
||
Other
|
1.7
|
|
|
1.6
|
|
|
6.3
|
|
||
Net sales
|
$
|
594.5
|
|
|
$
|
589.3
|
|
|
0.9
|
|
|
Three Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage Change
|
|||||
Acthar
|
$
|
319.4
|
|
|
$
|
298.3
|
|
|
7.1
|
%
|
Inomax
|
125.5
|
|
|
121.1
|
|
|
3.6
|
|
||
Ofirmev
|
75.7
|
|
|
70.7
|
|
|
7.1
|
|
||
Therakos immunotherapy
|
51.2
|
|
|
52.5
|
|
|
(2.5
|
)
|
||
Hemostasis products
|
13.5
|
|
|
13.9
|
|
|
(2.9
|
)
|
||
Other
|
9.2
|
|
|
32.8
|
|
|
(72.0
|
)
|
||
Specialty Brands
|
$
|
594.5
|
|
|
$
|
589.3
|
|
|
0.9
|
|
|
Three Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change |
|||||
U.S.
|
$
|
176.0
|
|
|
$
|
227.4
|
|
|
(22.6
|
)%
|
Europe, Middle East and Africa
|
24.9
|
|
|
22.5
|
|
|
10.7
|
|
||
Other
|
15.1
|
|
|
13.5
|
|
|
11.9
|
|
||
Net sales
|
$
|
216.0
|
|
|
$
|
263.4
|
|
|
(18.0
|
)
|
|
Three Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage Change
|
|||||
Hydrocodone (API) and hydrocodone-containing tablets
|
$
|
23.0
|
|
|
$
|
38.2
|
|
|
(39.8
|
)%
|
Oxycodone (API) and oxycodone-containing tablets
|
25.1
|
|
|
30.6
|
|
|
(18.0
|
)
|
||
Methylphenidate ER
|
20.2
|
|
|
24.3
|
|
|
(16.9
|
)
|
||
Other controlled substances
|
107.7
|
|
|
124.7
|
|
|
(13.6
|
)
|
||
Other products
|
40.0
|
|
|
45.6
|
|
|
(12.3
|
)
|
||
Specialty Generics
|
$
|
216.0
|
|
|
$
|
263.4
|
|
|
(18.0
|
)
|
|
Three Months Ended
|
||||||||||||
|
June 30, 2017
|
|
June 24, 2016
|
||||||||||
Specialty Brands
|
$
|
274.1
|
|
|
46.1
|
%
|
|
$
|
302.1
|
|
|
51.3
|
%
|
Specialty Generics
|
63.3
|
|
|
29.3
|
|
|
98.1
|
|
|
37.2
|
|
||
Segment operating income
|
337.4
|
|
|
41.6
|
|
|
400.2
|
|
|
46.9
|
|
||
Unallocated amounts:
|
|
|
|
|
|
|
|
||||||
Corporate and allocated expenses
|
(49.1
|
)
|
|
|
|
(34.1
|
)
|
|
|
||||
Intangible asset amortization
|
(174.7
|
)
|
|
|
|
(175.8
|
)
|
|
|
||||
Restructuring and related charges, net
(1)
|
(1.5
|
)
|
|
|
|
(15.2
|
)
|
|
|
||||
Total operating income
|
$
|
112.1
|
|
|
|
|
$
|
175.1
|
|
|
|
(1)
|
Includes restructuring-related accelerated depreciation.
|
|
Six Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change
|
|||||
Specialty Brands
|
$
|
1,151.7
|
|
|
$
|
1,124.3
|
|
|
2.4
|
%
|
Specialty Generics
|
454.6
|
|
|
527.8
|
|
|
(13.9
|
)
|
||
Net sales of operating segments
|
1,606.3
|
|
|
1,652.1
|
|
|
(2.8
|
)
|
||
Other
(1)
|
29.1
|
|
|
30.3
|
|
|
(4.0
|
)
|
||
Net sales
|
$
|
1,635.4
|
|
|
$
|
1,682.4
|
|
|
(2.8
|
)
|
(1)
|
Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business.
|
|
Six Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change |
|||||
U.S.
|
$
|
1,113.7
|
|
|
$
|
1,086.2
|
|
|
2.5
|
%
|
Europe, Middle East and Africa
|
34.5
|
|
|
35.1
|
|
|
(1.7
|
)
|
||
Other
|
3.5
|
|
|
3.0
|
|
|
16.7
|
|
||
Net sales
|
$
|
1,151.7
|
|
|
$
|
1,124.3
|
|
|
2.4
|
|
|
Six Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage Change
|
|||||
Acthar
|
$
|
591.2
|
|
|
$
|
546.7
|
|
|
8.1
|
%
|
Inomax
|
253.9
|
|
|
236.6
|
|
|
7.3
|
|
||
Ofirmev
|
149.1
|
|
|
141.8
|
|
|
5.1
|
|
||
Therakos immunotherapy
|
102.4
|
|
|
102.7
|
|
|
(0.3
|
)
|
||
Hemostasis products
|
26.6
|
|
|
25.3
|
|
|
5.1
|
|
||
Other
|
28.5
|
|
|
71.2
|
|
|
(60.0
|
)
|
||
Specialty Brands
|
$
|
1,151.7
|
|
|
$
|
1,124.3
|
|
|
2.4
|
|
|
Six Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage
Change |
|||||
U.S.
|
$
|
373.0
|
|
|
$
|
454.9
|
|
|
(18.0
|
)%
|
Europe, Middle East and Africa
|
52.3
|
|
|
42.7
|
|
|
22.5
|
|
||
Other
|
29.3
|
|
|
30.2
|
|
|
(3.0
|
)
|
||
Net sales
|
$
|
454.6
|
|
|
$
|
527.8
|
|
|
(13.9
|
)
|
|
Six Months Ended
|
|
|
|||||||
|
June 30,
2017 |
|
June 24,
2016 |
|
Percentage Change
|
|||||
Hydrocodone (API) and hydrocodone-containing tablets
|
$
|
53.3
|
|
|
$
|
79.0
|
|
|
(32.5
|
)%
|
Oxycodone (API) and oxycodone-containing tablets
|
47.2
|
|
|
68.5
|
|
|
(31.1
|
)
|
||
Methylphenidate ER
|
43.9
|
|
|
48.9
|
|
|
(10.2
|
)
|
||
Other controlled substances
|
215.1
|
|
|
246.6
|
|
|
(12.8
|
)
|
||
Other products
|
95.1
|
|
|
84.8
|
|
|
12.1
|
|
||
Specialty Generics
|
$
|
454.6
|
|
|
$
|
527.8
|
|
|
(13.9
|
)
|
|
Six Months Ended
|
||||||||||||
|
June 30, 2017
|
|
June 24, 2016
|
||||||||||
Specialty Brands
|
$
|
549.1
|
|
|
47.7
|
%
|
|
$
|
563.0
|
|
|
50.1
|
%
|
Specialty Generics
|
139.5
|
|
|
30.7
|
|
|
197.0
|
|
|
37.3
|
|
||
Segment operating income
|
688.6
|
|
|
42.9
|
|
|
760.0
|
|
|
46.0
|
|
||
Unallocated amounts:
|
|
|
|
|
|
|
|
||||||
Corporate and allocated expenses
|
(116.3
|
)
|
|
|
|
(59.5
|
)
|
|
|
||||
Intangible asset amortization
|
(349.8
|
)
|
|
|
|
(350.8
|
)
|
|
|
||||
Restructuring and related charges, net
(1)
|
(20.2
|
)
|
|
|
|
(25.3
|
)
|
|
|
||||
Non-restructuring impairment
|
—
|
|
|
|
|
(16.9
|
)
|
|
|
||||
Total operating income
|
$
|
202.3
|
|
|
|
|
$
|
307.5
|
|
|
|
(1)
|
Includes restructuring-related accelerated depreciation.
|
|
Six Months Ended
|
||||||
|
June 30,
2017 |
|
June 24,
2016 |
||||
Net cash from:
|
|
|
|
||||
Operating activities
|
$
|
222.5
|
|
|
$
|
683.0
|
|
Investing activities
|
465.4
|
|
|
(246.4
|
)
|
||
Financing activities
|
(702.2
|
)
|
|
(485.9
|
)
|
||
Effect of currency exchange rate changes on cash and cash equivalents
|
1.6
|
|
|
2.1
|
|
||
Net decrease in cash and cash equivalents
|
$
|
(12.7
|
)
|
|
$
|
(47.2
|
)
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk.
|
Item 4.
|
Controls and Procedures.
|
Item 1.
|
Legal Proceedings.
|
Item 1A.
|
Risk Factors.
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds.
|
|
Total Number of
Shares Purchased |
|
Average Price
Paid
Per Share
|
|
Total Number of
Shares Purchased as Part of Publicly Announced Plans or Programs |
|
Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under Plans or Programs
|
||||||
April 1, 2017 to April 28, 2017
|
96,604
|
|
|
$
|
37.71
|
|
|
123,265
|
|
|
$
|
985.0
|
|
April 29, 2017 to June 2, 2017
|
1,750,610
|
|
|
42.80
|
|
|
1,750,274
|
|
|
910.1
|
|
||
June 3, 2017 to June 30, 2017
|
503,602
|
|
|
40.85
|
|
|
500,591
|
|
|
889.7
|
|
Item 3.
|
Defaults Upon Senior Securities.
|
Item 4.
|
Mine Safety Disclosures.
|
Item 5.
|
Other Information.
|
Item 6.
|
Exhibits.
|
Exhibit
Number
|
|
Exhibit
|
|
|
|
3.1
|
|
Certificate of Incorporation of Mallinckrodt plc (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed July 1, 2013).
|
3.2
|
|
Amended and Restated Memorandum and Constitution of Mallinckrodt plc (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed March 1, 2017).
|
10.1
|
|
Mallinckrodt Pharmaceuticals Severance Plan for U.S. Officers and Executives, amended May 18, 2017.
|
10.2
|
|
Mallinckrodt Pharmaceuticals Change in Control Severance Plan for Certain U.S. Officers and Executives, amended May 18, 2017.
|
10.3
|
|
Mallinckrodt Pharmaceuticals Stock and Incentive Plan, amended May 18, 2017.
|
10.4
|
|
Amended and Restated Note Purchase Agreement, dated as of July 28, 2017, among Mallinckrodt Securitization S.À R.L., the persons from time to time party thereto as purchasers, PNC Bank, National Association, as administrative agent, and Mallinckrodt LLC, as initial servicer (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed August 1, 2017).
|
10.5
|
|
Amended and Restated Purchase and Sale Agreement, dated as of July 28, 2017, among the various entities party thereto from time to time as originators, Mallinckrodt LLC, as initial servicer, and Mallinckrodt Securitization S.À R.L., as buyer (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed August 1, 2017).
|
10.6
|
|
Form of Sale Agreement, dated as of July 28, 2017, between Mallinckrodt LLC and each Sub-Originator (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed August 1, 2017).
|
10.7
|
|
Performance Guaranty, dated as of July 28, 2014, by Mallinckrodt International Finance S.A. in favor of PNC Bank, National Association, as administrative agent (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed July 30, 2014).
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
32.1
|
|
Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
101
|
|
Interactive Data File (Form 10-Q for the quarterly period ended June 30, 2017 filed in XBRL). The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed."
|
|
MALLINCKRODT PUBLIC LIMITED COMPANY
|
|
|
|
|
|
By:
|
/s/ Matthew K. Harbaugh
|
|
|
Matthew K. Harbaugh
Executive Vice President and Chief Financial Officer
(principal financial officer)
|
ARTICLE I
|
PURPOSE, INTENT AND TERM OF PLAN......................................... 1
|
Section 1.01
|
Purpose and Intent of the Plan................................................................. 1
|
Section 1.02
|
Term of the Plan....................................................................................... 1
|
Section 1.03
|
Adoption of the Plan................................................................................ 1
|
ARTICLE II
|
DEFINITIONS......................................................................................... 2
|
Section 2.01
|
Alternative Position................................................................................. 2
|
Section 2.02
|
Annual Bonus.......................................................................................... 2
|
Section 2.03
|
Base Salary............................................................................................... 2
|
Section 2.04
|
Board........................................................................................................ 2
|
Section 2.05
|
Cause........................................................................................................ 2
|
Section 2.06
|
Claim........................................................................................................ 3
|
Section 2.07
|
Claimant................................................................................................... 3
|
Section 2.08
|
COBRA.................................................................................................... 3
|
Section 2.09
|
Code......................................................................................................... 3
|
Section 2.10
|
Committee ................................................................................................3
|
Section 2.11
|
Company.................................................................................................. 3
|
Section 2.12
|
Effective Date.......................................................................................... 3
|
Section 2.13
|
Eligible Employee ....................................................................................3
|
Section 2.14
|
Employee................................................................................................. 3
|
Section 2.15
|
Employer.................................................................................................. 4
|
Section 2.16
|
ERISA...................................................................................................... 4
|
Section 2.17
|
Exchange Act........................................................................................... 4
|
Section 2.18
|
Involuntary Termination.......................................................................... 4
|
Section 2.20
|
Key Employee.......................................................................................... 4
|
Section 2.19
|
Named Appeals Fiduciary ........................................................................4
|
Section 2.21
|
Officer...................................................................................................... 4
|
Section 2.22
|
Participant................................................................................................ 4
|
Section 2.23
|
Permanent Disability................................................................................ 4
|
Section 2.24
|
Plan.......................................................................................................... 4
|
Section 2.25
|
Plan Administrator................................................................................... 4
|
Section 2.26
|
Postponement Period............................................................................... 5
|
Section 2.27
|
Release..................................................................................................... 5
|
Section 2.28
|
Salary Continuation Benefits................................................................... 5
|
Section 2.29
|
Separation from Service........................................................................... 5
|
Section 2.30
|
Separation from Service Date.................................................................. 5
|
Section 2.31
|
Severance Benefits................................................................................... 5
|
Section 2.32
|
Severance Period...................................................................................... 5
|
Section 2.33
|
Subsidiary................................................................................................. 5
|
Section 2.34
|
Termination Date..................................................................................... 6
|
Section 2.35
|
Voluntary Termination............................................................................. 6
|
ARTICLE III
|
PARTICIPATION AND ELIGIBILITY FOR BENEFITS...................... 7
|
Section 3.01
|
Participation............................................................................................. 7
|
Section 3.02
|
Conditions................................................................................................ 7
|
ARTICLE IV
|
DETERMINATION OF SEVERANCE BENEFITS.............................. 9
|
Section 4.01
|
Amount of Severance Benefits Upon Involuntary Termination.............. 9
|
Section 4.02
|
Voluntary Termination; Termination for Death or Permanent
|
Section 4.03
|
Termination for Cause.................................................................. ..........12
|
Section 4.04
|
Reduction of Severance Benefits............................................................12
|
ARTICLE V
|
METHOD AND DURATION OF SEVERANCE BENEFIT PAYMENTS ..........................................................................................13
|
Section 5.01
|
Method of Payment................................................................................13
|
Section 5.02
|
Other Arrangements...............................................................................13
|
Section 5.03
|
Code Section 409A................................................................................13
|
Section 5.04
|
Termination of Eligibility for Benefits..................................................14
|
ARTICLE VI
|
THE PLAN ADMINISTRATOR...........................................................15
|
Section 6.01
|
Authority and Duties.................................................................... ..........15
|
Section 6.02
|
Compensation of the Plan Administrator................................................15
|
Section 6.03
|
Records, Reporting and Disclosure.............................................. ..........15
|
ARTICLE VII
|
AMENDMENT, TERMINATION AND DURATION..........................16
|
Section 7.01
|
Amendment, Suspension and Termination.............................................16
|
Section 7.02
|
Duration..................................................................................................16
|
ARTICLE VIII
|
DUTIES OF THE COMPANY AND THE COMMITTEE....................17
|
Section 8.01
|
Records...................................................................................................17
|
Section 8.02
|
Payment..................................................................................................17
|
Section 8.03
|
Discretion...............................................................................................17
|
ARTICLE IX
|
CLAIMS PROCEDURES......................................................................18
|
Section 9.01
|
Claim......................................................................................................18
|
Section 9.02
|
Initial Claim............................................................................................18
|
Section 9.03
|
Appeals of Denied Administrative Claims.............................................18
|
Section 9.04
|
Appointment of the Named Appeals Fiduciary......................................19
|
ARTICLE X
|
MISCELLANEOUS...............................................................................20
|
Section 10.01
|
Non-Alienation of Benefits ...................................................................20
|
Section 10.02
|
Notices ...................................................................................................20
|
Section 10.03
|
Successors .............................................................................................20
|
Section 10.04
|
Other Payments......................................................................................20
|
Section 10.05
|
No Mitigation.........................................................................................20
|
Section 10.06
|
No Contract of Employment..................................................................20
|
Section 10.07
|
Severability of Provisions......................................................................20
|
Section 10.08
|
Heirs, Assigns, and Personal Representatives........................................21
|
Section 10.09
|
Headings, Captions and Titles................................................................21
|
Section 10.10
|
Gender and Number...............................................................................21
|
Section 10.11
|
Unfunded Plan.......................................................................................21
|
Section 10.12
|
Payments to Incompetent Persons.........................................................21
|
Section 10.13
|
Lost Payees............................................................................................21
|
Section 10.14
|
Controlling Law.....................................................................................21
|
President and Chief Executive Officer
|
24 month Severance Period
|
Members of the Executive Committee (Titles of Executive Vice Presidents and Senior Vice Presidents)
|
18 month Severance Period
|
Any other Eligible Employees (Titles of Senior Vice President and Vice President)
|
12 month Severance Period
|
President and Chief Executive Officer
|
2x Annual Bonus
|
Members of the Executive Committee (Titles of Executive Vice Presidents and Senior Vice Presidents)
|
1.5x Annual Bonus
|
Any other Eligible Employees (Titles of Senior Vice President and Vice President)
|
1x Annual Bonus
|
ARTICLE I
|
BACKGROUND, PURPOSE AND TERM OF PLAN.......................................1
|
Section 1.01
|
Purpose and Intent of the Plan.................................................................1
|
Section 1.02
|
Term of the Plan.......................................................................................1
|
Section 1.03
|
Adoption of the Plan................................................................................1
|
ARTICLE II
|
DEFINITIONS....................................................................................................2
|
Section 2.01
|
“Annual Bonus”......................................................................................2
|
Section 2.02
|
“Base Salary”..........................................................................................2
|
Section 2.03
|
“Board”...................................................................................................2
|
Section 2.04
|
“Cause”...................................................................................................2
|
Section 2.05
|
“Change in Control”...............................................................................2
|
Section 2.06
|
“Change in Control Benefits”.................................................................2
|
Section 2.07
|
“Change in Control Termination”
......................................................................
2
|
Section 2.08
|
“COBRA”...............................................................................................2
|
Section 2.09
|
“Code”....................................................................................................2
|
Section 2.10
|
“Committee”...........................................................................................2
|
Section 2.11
|
“Company”.............................................................................................3
|
Section 2.12
|
“Effective Date”......................................................................................3
|
Section 2.13
|
“Eligible Employee”...............................................................................3
|
Section 2.14
|
“Employee”.............................................................................................3
|
Section 2.15
|
“Employer”.............................................................................................3
|
Section 2.16
|
“ERISA”.................................................................................................3
|
Section 2.17
|
“Exchange Act”......................................................................................3
|
Section 2.18
|
“Executive Severance Plan”...................................................................3
|
Section 2.19
|
“Good Reason Resignation”...................................................................3
|
Section 2.20
|
“Involuntary Termination”......................................................................4
|
Section 2.21
|
“Key Employee”.....................................................................................4
|
Section 2.22
|
“Notice Pay”...........................................................................................4
|
Section 2.23
|
“Officer”.................................................................................................4
|
Section 2.24
|
“Participant”...........................................................................................4
|
Section 2.25
|
“Permanent Disability”..........................................................................4
|
Section 2.26
|
“Plan”.....................................................................................................5
|
Section 2.27
|
“Plan Administrator”..............................................................................5
|
Section 2.28
|
“Postponement Period”..........................................................................5
|
Section 2.29
|
“Release”................................................................................................5
|
Section 2.30
|
“Separation from Service”.....................................................................5
|
Section 2.31
|
“Separation from Service Date”.............................................................5
|
Section 2.32
|
“Severance Benefits”..............................................................................5
|
Section 2.33
|
“Severance Period”.................................................................................5
|
Section 2.34
|
“Subsidiary”............................................................................................5
|
Section 2.35
|
“Successor”.............................................................................................6
|
Section 2.36
|
“Voluntary Resignation”.........................................................................6
|
ARTICLE III
|
PARTICIPATION AND ELIGIBILITY FOR BENEFITS.................................7
|
Section 3.01
|
Participation............................................................................................7
|
Section 3.02
|
Conditions...............................................................................................7
|
ARTICLE IV
|
DETERMINATION OF SEVERANCE BENEFITS.........................................9
|
Section 4.01
|
Amount of Severance Benefits Upon Involuntary Termination and Good Reason Resignation................................................................................9
|
Section 4.02
|
Voluntary Resignation; Termination for Death or Permanent
|
Section 4.03
|
Termination for Cause............................................................................11
|
Section 4.04
|
Reduction of Severance Benefits...........................................................11
|
ARTICLE V
|
METHOD, DURATION AND LIMITATION OF SEVERANCE BENEFIT PAYMENTS.......................................................................................................13
|
Section 5.01
|
Method of Payment................................................................................13
|
Section 5.02
|
Other Arrangements...............................................................................13
|
Section 5.03
|
Code Section 409A.................................................................................13
|
Section 5.04
|
Termination of Eligibility for Benefits...................................................14
|
Section 5.05
|
Limitation on Benefits............................................................................14
|
ARTICLE VI
|
THE PLAN ADMINISTRATOR........................................................................16
|
Section 6.01
|
Authority and Duties..............................................................................16
|
Section 6.02
|
Compensation of the Plan Administrator...............................................16
|
Section 6.03
|
Records, Reporting and Disclosure........................................................16
|
ARTICLE VII
|
AMENDMENT, TERMINATION AND DURATION......................................17
|
Section 7.01
|
Amendment, Suspension and Termination.............................................17
|
Section 7.02
|
Duration..................................................................................................17
|
ARTICLE VIII
|
DUTIES OF THE COMPANY AND THE COMMITTEE................................17
|
Section 8.01
|
Records...................................................................................................17
|
Section 8.02
|
Payment..................................................................................................17
|
Section 8.03
|
Discretion................................................................................................17
|
ARTICLE IX
|
CLAIMS PROCEDURES..................................................................................18
|
Section 9.01
|
Claim......................................................................................................18
|
Section 9.02
|
Initial Claim............................................................................................18
|
Section 9.03
|
Appeals of Denied Administrative Claims.............................................18
|
Section 9.04
|
Appointment of the Named Appeals Fiduciary......................................19
|
ARTICLE X
|
MISCELLANEOUS...........................................................................................19
|
Section 10.01
|
Non-Alienation of Benefits....................................................................19
|
Section 10.02
|
Notices....................................................................................................19
|
Section 10.03
|
Successors...............................................................................................20
|
Section 10.04
|
Other Payments.......................................................................................20
|
Section 10.05
|
No Mitigation.........................................................................................20
|
Section 10.06
|
No Contract of Employment...................................................................20
|
Section 10.07
|
Severability of Provisions.......................................................................20
|
Section 10.08
|
Heirs, Assigns, and Personal Representatives........................................20
|
Section 10.09
|
Headings and Captions...........................................................................20
|
Section 10.10
|
Gender and Number................................................................................20
|
Section 10.11
|
Unfunded Plan........................................................................................20
|
Section 10.12
|
Payments to Incompetent Persons..........................................................20
|
Section 10.13
|
Lost Payees.............................................................................................21
|
Section 10.14
|
Controlling Law......................................................................................21
|
President and Chief Executive Officer
|
24 month Severance Period
|
Members of the Executive Committee (Titles of Executive Vice Presidents and Senior Vice Presidents)
|
18 month Severance Period
|
Any other Eligible Employees (Titles of Senior Vice President and Vice President)
|
12 month Severance Period
|
President and Chief Executive Officer
|
2x Annual Bonus
|
Members of the Executive Committee (Titles of Executive Vice Presidents and Senior Vice Presidents)
|
1.5x Annual Bonus
|
Any other Eligible Employees (Titles of Senior Vice President and Vice President)
|
1x Annual Bonus
|
(a)
|
“
Stock Options”
awarded pursuant to Section 4.3;
|
(b)
|
“
Stock Appreciation Rights”
awarded pursuant to Section 4.3;
|
(c)
|
“
Annual Performance Bonuses”
awarded pursuant to Section 4.4;
|
(d)
|
“Long-Term Performance Awards”
awarded pursuant to Section 4.5;
|
(e)
|
“Other Stock-Based Awards”
awarded pursuant to Section 4.6;
|
(f)
|
“Director Awards”
awarded pursuant to Section 4.7; and
|
(g)
|
“Substitute Awards”
awarded pursuant to Section 4.8.
|
(a)
|
any “person” (as defined in Section 13(d) and 14(d) of the Exchange Act, excluding for this purpose, (i) the Company or any Subsidiary or (ii) any employee benefit plan of the Company or any Subsidiary (or any person or entity organized, appointed or established by the Company for or pursuant to the terms of any such plan that acquires beneficial ownership of voting securities of the Company), is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act) directly or indirectly of securities of the Company representing more than 30 percent of the combined voting power of the Company's then outstanding securities; provided, however, that no Change in Control will be deemed to have occurred as a result of a change in ownership percentage resulting solely from an acquisition of securities by the Company; or
|
(b)
|
persons who, as of the Effective Date constitute the Board (the “Incumbent Directors”) cease for any reason (including without limitation, as a result of a tender offer, proxy contest, merger or similar transaction) to constitute at least a majority thereof, provided that any person becoming a Director of the Company subsequent to the Effective Date shall be considered an Incumbent Director if such person's election or nomination for election was approved by a vote of at least 50 percent of the Incumbent Directors; but provided further, that any such person whose initial assumption of office is in connection with an actual or threatened proxy contest relating to the election of members of the Board or other actual or threatened solicitation of proxies or consents by or on behalf of a “person” (as defined in Section 13(d) and 14(d) of the Exchange Act) other than the Board, including by reason of agreement intended to avoid or settle any such actual or threatened contest or solicitation, shall not be considered an Incumbent Director; or
|
(c)
|
consummation of a reorganization, merger or consolidation or sale or other disposition of at least 80 percent by value of the assets of the Company (a “Business Combination”), in each case, unless, following such Business Combination, all or substantially all of the individuals and entities who were the beneficial owners of outstanding voting securities of the Company immediately prior to such Business Combination beneficially own directly or indirectly more than 50 percent of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, of the company resulting from such Business Combination (including, without limitation, a company which, as a result of such transaction, owns the Company or all or substantially all of the Company's assets either directly or through one or more Subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the outstanding voting securities of the Company; or
|
(d)
|
approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.
|
(a)
|
termination of the Participant’s employment by the Company for any reason other than for Cause, Disability or death;
|
(b)
|
termination of the Participant’s employment by the Participant after one of the following events, provided that the Participant’s termination of employment occurs within sixty (60) days after the occurrence of any such event:
|
(i)
|
the Company, without the Participant’s consent, requires the Participant to relocate to a principal place of employment more than fifty (50) miles from his or her existing place of employment, which materially increases the Participant’s commuting time; or
|
(ii)
|
the Company, without the Participant’s consent, materially reduces the Participant’s base salary, target annual bonus opportunity, or retirement, welfare, target share incentive opportunity, and other benefits taken as a whole, as in effect immediately prior to the Change in Control;
|
(a)
|
Interpret and administer the Plan and any instrument or agreement relating to the Plan;
|
(b)
|
Prescribe the rules and regulations that it deems necessary for the proper operation and administration of the Plan, and amend or rescind any existing rules or regulations relating to the Plan;
|
(c)
|
Select Employees to receive Awards under the Plan;
|
(d)
|
Determine the form of an Award, the number of Shares subject to each Award, all the terms and conditions of an Award, including, without limitation, the conditions on exercise or vesting, the designation of Stock Options as Incentive Stock Options or Nonqualified Stock Options, and the circumstances under which an Award may be settled in cash or Shares or may be cancelled, forfeited or suspended, and the terms of each Award Certificate;
|
(e)
|
Determine whether Awards will be granted singly, in combination or in tandem;
|
(f)
|
Establish and interpret Performance Measures (or, as applicable, other performance criteria) in connection with Annual Performance Bonuses and Long-Term Performance Awards, evaluate the level of performance over a Performance Cycle and certify the level of performance attained with respect to Performance Measures (or other performance criteria, as applicable);
|
(g)
|
Subject to Sections 6.1 and 7.12, waive or amend any terms, conditions, restriction or limitation on an Award, except that the prohibition on the repricing of Stock Options and Stock Appreciation Rights without shareholder approval, as described in Section 4.3(g), may not be waived;
|
(h)
|
Make any adjustments to the Plan (including but not limited to adjustment of the number of Shares available under the Plan or any Award) and any Award granted under the Plan as shall be appropriate pursuant to Section 5.3;
|
(i)
|
Determine and set forth in the applicable Award Certificate the circumstances under which Awards may be deferred and the extent to which a deferral will be credited with Dividend Equivalents and interest thereon;
|
(j)
|
In accordance with Section 7.1, determine and set forth in the applicable Award Certificate whether a Nonqualified Stock Option, Restricted Share or other Award may be transferable to family members, a family trust or a family partnership;
|
(k)
|
Establish any subplans and make any modifications to the Plan, without amending the Plan, or to Awards made hereunder (including the establishment of terms and conditions in the Award Certificate not otherwise inconsistent
|
(l)
|
Appoint such agents as it shall deem appropriate for the proper administration of the Plan; and
|
(m)
|
Take any and all other actions it deems necessary or advisable for the proper operation or administration of the Plan.
|
(a)
|
Form.
Stock Options granted under the Plan will, at the discretion of the Committee and as set forth in the Award Certificate, be in the form of Incentive Stock Options, Nonqualified Stock Options or a combination of the two. If an Incentive Stock Option and a Nonqualified Stock Option are granted to the same Participant under the Plan at the same time, the form of each will be clearly identified, and they will be deemed to have been granted in separate grants. In no event will the exercise of one Stock Option affect the right to exercise the other Stock Option. Stock Appreciation Rights may be granted either alone or concurrently with Nonqualified Stock Options and the amount of Shares attributable to each Stock Appreciation Right shall be set forth in the applicable Award Certificate on or before the grant date.
|
(b)
|
Exercise Price.
Other than with respect to Substitute Awards described in Section 4.8, the Committee will set the Exercise Price of Stock Options or Stock Appreciation Rights granted under the Plan at a price that is equal to or greater than the Fair Market Value of a Share on the date of grant, subject to adjustment as provided in Section 5.3. The Exercise Price of Incentive Stock Options will be equal to or greater than 110 percent of the Fair Market Value of a Share as of the date of grant if the Participant receiving the Incentive Stock Options owns shares possessing more than 10 percent of the total combined voting power of all classes of shares of the Company or any subsidiary or parent corporation of the Company, as defined in Section 424 of the Code. The Exercise Price of
|
(c)
|
Term and Timing of Exercise.
Each Stock Option or Stock Appreciation Right granted under the Plan will be exercisable in whole or in part, subject to the following conditions, unless determined otherwise by the Committee:
|
(i)
|
The term of each Stock Option and Stock Appreciation Right shall be determined by the Committee and set forth in the applicable Award Certificate, but in no event shall the term thereof exceed ten (10) years from the date of its grant. Notwithstanding the foregoing, in the event that on the last business day of the term of a Stock Option (other than an Incentive Stock Option) or Stock Appreciation Right (i) the exercise of the Award is prohibited by applicable law or (ii) Shares may not be purchased or sold by certain employees or directors of the Company due to the “black-out period” of a Company policy or a “lock-up” agreement undertaken in connection with an issuance of securities by the Company, the term of the Stock Option or Stock Appreciation Right shall be extended for a period of thirty (30) days following the end of the legal prohibition, black-out period or lock-up agreement. Moreover, notwithstanding the foregoing, an Award Certificate may provide that if on the last day of the term of a Stock Option or Stock Appreciation Right the Fair Market Value of one Share exceeds the option or grant price per Share, the Participant has not exercised the Stock Option, Stock Appreciation Right or tandem Award, and the Award has not expired, the Stock Option or Stock Appreciation Right shall be deemed to have been exercised by the Participant on such day with payment made by withholding Shares otherwise issuable in connection with the exercise of the Stock Option or Stock Appreciation Right. In such event, the Company shall deliver to the Participant the number of Shares for which the Stock Option or Stock Appreciation Right was deemed exercised, less the number of Shares required to be withheld for the payment of the total purchase price for a Stock Option and required withholding taxes for both Stock Options and Stock Appreciation Rights; provided, however, any fractional Share shall be settled in cash.
|
(ii)
|
A Stock Option or Stock Appreciation Right will become exercisable at such times and in such manner as determined by the Committee and set forth in the applicable Award Certificate.
|
(iii)
|
Unless the applicable Award Certificate provides otherwise, upon the death, Disability, Normal Retirement or a Change in Control Termination of a Participant who has outstanding Stock Options or Stock Appreciation Rights, the unvested Stock Options or Stock Appreciation Rights will fully vest. Unless the applicable Award Certificate or the remainder of this Section 4.3(c) provides otherwise, the Participant’s Stock Options and Stock Appreciation Rights will lapse, and will not thereafter be exercisable, upon the earlier of (A) their original expiration date or (B) the date that is three (3) years after the date on which the Participant dies, incurs a Disability or retires due to Normal Retirement.
|
(iv)
|
Unless the applicable Award Certificate provides otherwise, upon the Termination of Employment of a Participant for any reason other than the Participant's death, Disability, Normal Retirement or a Change in Control Termination, if the Participant’s termination qualifies as Early Retirement, a pro rata portion of the Participant’s Stock Options and Stock Appreciation Rights will vest so that the total number of vested Stock Options or Stock Appreciation Rights held by the Participant at Termination of Employment (including those that have already vested as of such date) will be equal to the total number of Stock Options or Stock Appreciation Rights originally granted to the Participant under the applicable Award multiplied by a fraction, the numerator of which is the period of time (in whole months) that have elapsed since the date of grant, and the denominator of which is the number of months set forth in the applicable Award Certificate that is required to attain full vesting. Unless the Award Certificate provides otherwise, such Participant's Stock Options and Stock Appreciation Rights will lapse, and will not thereafter be exercisable, upon the earlier of (A) their original expiration date or (B) the date that is three (3) years after the date of Termination of Employment.
|
(v)
|
Unless the applicable Award Certificate provides otherwise, upon the Termination of Employment of a Participant that does not meet the requirements of paragraphs (iii) or (iv) above, any unvested Stock Options or Stock Appreciation Rights will be forfeited. Unless the applicable Award Certificate provides otherwise, any Stock Options or Stock Appreciation Rights that are vested as of such Termination of Employment will lapse, and will not thereafter be exercisable, upon the earlier of (A) their original expiration date or (B) the date that is ninety (90) days after the date of such Termination of Employment.
|
(vi)
|
Stock Options and Stock Appreciation Rights of a deceased Participant may be exercised only by the estate of the Participant or by the person given authority to exercise the Stock Options or Stock Appreciation Rights by the Participant's will or by operation of law. If a Stock Option or Stock Appreciation Right is exercised by the executor or administrator of a deceased Participant, or by the person or persons to whom the Stock Option or Stock Appreciation Right has been transferred by the Participant's will or the applicable laws of descent and distribution, the Company will be under no obligation to deliver Shares or cash until the Company is satisfied that the person exercising the Stock Option or Stock Appreciation Right is the duly appointed executor or administrator of the deceased Participant or the person to whom the Stock Option or Stock Appreciation Right has been transferred by the Participant's will or by applicable laws of descent and distribution.
|
(vii)
|
A Stock Appreciation Right granted in tandem with a Stock Option is subject to the same terms and conditions as the related Stock Option and will be exercisable only to the extent that the related Stock Option is exercisable. When either a Stock Option or a Stock Appreciation Right granted in tandem with each other is exercised, the tandem Stock Option or Stock Appreciation Right, as applicable, shall expire.
|
(d)
|
Payment of Exercise Price.
The Exercise Price of a Stock Option must be paid in full when the Stock Option is exercised. Shares will be issued and delivered only upon receipt of payment. Payment of the Exercise Price may be made in cash or by certified check, bank draft, wire transfer, or postal or express money order, provided that the format is approved by the Company or a designated third-party administrator. The Committee, in its discretion may also allow payment to be made by any of the following methods, as set forth in the applicable Award Certificate:
|
(i)
|
Delivering a properly executed exercise notice to the Company or its agent, together with irrevocable instructions to a broker to deliver to the Company, within the typical settlement cycle for the sale of equity securities on the relevant trading market (or otherwise in accordance with the provisions of Regulation T issued by the Federal Reserve Board), the amount of sale proceeds with respect to the portion of the Shares to be acquired having a Fair Market Value on the date of exercise equal to the sum of the applicable portion of the Exercise Price being so paid;
|
(ii)
|
Subject to any requirements of applicable law and regulations, tendering (actually or by attestation) to the Company or its agent previously acquired Shares that have a Fair Market Value on the day prior to the date of exercise equal to the applicable portion of the Exercise Price being so paid; or
|
(iii)
|
Subject to any requirements of applicable law and regulations, instructing the Company to reduce the number of Shares that would otherwise be issued by such number of Shares as have in the aggregate a Fair Market Value on the date of exercise equal to the applicable portion of the Exercise Price being so paid.
|
(e)
|
Incentive Stock Options.
Incentive Stock Options granted under the Plan will be subject to the following additional conditions, limitations and restrictions:
|
(i)
|
Eligibility.
Incentive Stock Options may be granted only to Employees of the Company or a Subsidiary that is a subsidiary or parent corporation of the Company within the meaning of Code Section 424.
|
(ii)
|
Timing of Grant.
No Incentive Stock Option will be granted under the Plan after the 10-year anniversary of the date on which the Plan is adopted by the Board or, if earlier, the date on which the Plan was approved by shareholders.
|
(iii)
|
Amount of Award.
Subject to Section 5.3 of the Plan, no more than 10 million Shares may be available for grant in the form of Incentive Stock Options. The aggregate Fair Market Value (as of the date of grant) of the Shares with respect to which the Incentive Stock Options awarded to any Employee first become exercisable during any calendar year may not exceed $100,000 (U.S.). For purposes of this $100,000 (U.S.) limit, the Employee's Incentive Stock Options under this Plan and all other plans maintained by the Company and its Subsidiaries will be aggregated. To the extent any Incentive Stock Option would exceed the $100,000 (U.S.) limit, the Incentive Stock Option will afterwards be treated as a Nonqualified Stock Option to the extent required by the Code and underlying regulations and rulings.
|
(iv)
|
Timing of Exercise.
If the Committee exercises its discretion in the Award Certificate to permit an Incentive Stock Option to be exercised by a Participant more than three months after the Participant has ceased being
|
(v)
|
Transfer Restrictions.
In no event will the Committee permit an Incentive Stock Option to be transferred by an Employee other than by will or the laws of descent and distribution, and any Incentive Stock Option awarded under this Plan will be exercisable only by the Employee during the Employee's lifetime.
|
(f)
|
Exercise of Stock Appreciation Rights.
Upon exercise of a Participant's Stock Appreciation Rights, the Company will pay cash or Shares or a combination of cash and Shares, in the discretion of the Committee and as described in the Award Certificate. Cash payments will be equal to the excess of the Fair Market Value of a Share on the date of exercise over the Exercise Price, for each Share for which a Stock Appreciation Right was exercised. If Shares are paid for the Stock Appreciation Right, the Participant will receive a number of whole Shares equal to the quotient of the cash payment amount divided by the Fair Market Value of a Share on the date of exercise.
|
(g)
|
No Repricing.
Except as otherwise provided in Section 5.3 or in connection with a Change in Control, in no event will the Committee decrease the Exercise Price of a Stock Option or Stock Appreciation Right after the date of grant or cancel outstanding Stock Options or Stock Appreciation Rights at a time when the exercise price therefor is less than the Fair Market Value of the Shares subject to such Award and issue cash in exchange for such cancellation or grant replacement Stock Options or Stock Appreciation Rights with a lower Exercise Price than that of the replaced Stock Options or Stock Appreciation Rights or other Awards without first obtaining the approval of the holders of a majority of the Shares who are present in person or by proxy at a meeting of the Company’s shareholders and entitled to vote.
|
(a)
|
Section 162(m) of the Code.
The Committee may determine that Annual Performance Bonuses made to Covered Employees should be structured to be “performance-based compensation” for purposes of Section 162(m) of the Code. If the Committee action granting such Awards or the Award Certificates so provide, this Section 4.4 shall be interpreted in a manner that satisfies the applicable requirements of Section 162(m)(4)(C) of the Code and related regulations, and the Plan shall be operated so that the Company may take a full tax deduction for Annual Performance Bonuses. If any provision of this Plan or any Annual Performance Bonus would otherwise frustrate or conflict with this intent, the provision will be interpreted and deemed amended so as to avoid this conflict.
|
(b)
|
Performance Cycles.
Annual Performance Bonuses will be awarded in connection with a twelve (12) month Performance Cycle, which will be the fiscal year of the Company.
|
(c)
|
Eligible Participants.
Within ninety (90) days after the commencement of a Performance Cycle, the Committee will determine the Reporting Persons who will be eligible to receive an Annual Performance Bonus under the Plan. If an individual becomes a Reporting Person after this ninety (90) day period, the Committee may determine that such Reporting Person is eligible to receive a pro rata Annual Performance Bonus under the Plan.
|
(d)
|
Performance Measures; Targets; Award Criteria.
|
(i)
|
Within ninety (90) days after the commencement of the service period to which a Performance Cycle relates, the Committee will fix and establish in writing (A) the Performance Measures that will apply to that Performance Cycle; (B) the Target Bonus which may be earned by each Participant; and (C) subject to subsection (d) below, the criteria for computing the amount that will be paid with respect to each level of
|
(ii)
|
The Committee, in its discretion, may, on a case-by-case basis, reduce, but not increase, the amount otherwise payable to any Covered Employee with respect to any given Performance Cycle, provided, however, that no reduction will result in an increase in the amount payable under any Annual Performance Bonus of another Covered Employee.
|
(e)
|
Payment, Certification.
No Annual Performance Bonus will be paid to any Reporting Person until the Committee certifies in writing the level of performance attained for the Performance Cycle in relation to the applicable Performance Measures. In applying Performance Measures, the Committee (i) shall make adjustments for events listed in Section 5.3 in accordance therewith and (ii) may, in its discretion, exclude the effect of unusual or infrequently occurring items, including, but not limited to the following, as set forth in the Award Certificate or action of the Committee granting the Award: the cumulative effect of changes in the law, regulations or accounting rules, and other items, all determined in accordance with GAAP (to the extent applicable and unless specified otherwise in the Award Certificate or action of the Committee granting the Award) and identified in financial statements, notes to the financial statements or discussion and analysis of management; asset write downs; litigation or claim judgments or settlements; any reorganization and restructuring programs; acquisitions or divestitures; and foreign exchange gains and losses.; provided that the determination by the Committee that Performance Measures shall be adjusted for items in accordance with this clause (ii) shall be made no later than ninety (90) days after the commencement of any applicable Performance Cycle in respect of Annual Performance Bonuses awarded to Covered Employees.
|
(f)
|
Form of Payment.
Annual Performance Bonuses will be paid in cash, Shares or such other Awards as determined by the Committee. All such Performance Bonuses shall be paid no later than the 15th day of the third month following the end of the calendar year (or, if later, following the end of the Company's fiscal year) in which such Performance Bonuses are no longer subject to a substantial risk of forfeiture (as determined for purposes of Section 409A of the Code), except to the extent that the Committee determines or a Participant has elected to defer payment under the terms of a duly authorized deferred compensation arrangement or Award, in which case the terms of such arrangement or Award shall govern.
|
(g)
|
Acceleration.
Each Participant who is eligible to receive an Annual Performance Bonus with respect to a Performance Cycle during which a Change of Control occurs will, except as otherwise provided below, be deemed to have achieved a level of performance, as of the date of Change in Control, that would cause all (100%) of the Participant's Target Bonus to become payable at such times and in such manner as determined in the sole discretion of the Committee. Notwithstanding the previous sentence, if (i) a surviving entity maintains the Performance Cycle in which a Change in Control occurs, or otherwise provides for the payment of an Annual Performance Bonus based on the level of performance attained for such Performance Cycle in relation to the Performance Measures established for such Performance Cycle (including Performance Measures that were adjusted or modified as a result of the Change in Control) and (ii) the Annual Performance Bonus based on the level of performance attained for such Performance Cycle exceeds all (100%) of the Participant’s Target Bonus, then each Participant who is eligible to receive an Annual Performance Bonus with respect to such Performance Cycle shall receive an Annual Performance Bonus based on the level of performance attained for such Performance Cycle at such times and in such manner as determined in the sole discretion of the Committee, or successor to the Committee. If a Participant’s employment is terminated before the end of the original Performance Cycle due to death, Disability, Normal Retirement, or by the Company without Cause, the Award payable to such Participant may, in the discretion of the Committee, be proportionately reduced based on the period of actual employment during the applicable Performance Cycle. Notwithstanding the above, the time and manner of any payments made pursuant to this Section 4.4(g) shall comply with Section 4.4(e) above.
|
(a)
|
Section 162(m) of the Code.
The Committee may determine that Long-Term Performance Awards made to Covered Employees should be structured to be "performance-based compensation" for purposes of Section 162(m) of the Code. If the Committee action granting such Award or the Award Certificates so provide, this Section 4.5 shall be interpreted in a manner that satisfies the applicable requirements of Section 162(m)(4)(C) of the Code and related regulations with respect to Long-Term Performance awards made to Covered Employees, and the Plan shall be operated so that the Company may take a full tax deduction for Long-Term Performance Awards. If any provision of this Plan or any Long-Term Performance Award would otherwise frustrate or conflict with this intent, the provision will be interpreted and deemed amended so as to avoid this conflict.
|
(b)
|
Performance Cycles.
Long-Term Performance Awards will be awarded in connection with a Performance Cycle, as determined by the Committee in its discretion, provided, however, that a Performance Cycle may be no shorter than twelve (12) months.
|
(c)
|
Eligible Participants.
Within ninety (90) days after the commencement of a Performance Cycle, the Committee will determine the Employees who will be eligible to receive a Long-Term Performance Award for the Performance Cycle, provided that the Committee may determine the eligibility of any Employee other than a Covered Employee after the expiration of this ninety (90) day period.
|
(d)
|
Performance Measures; Targets; Award Criteria.
|
(i)
|
Within ninety (90) days after the commencement of the service period to which a Performance Cycle relates, the Committee will fix and establish in writing (A) the Performance Measures that will apply to that Performance Cycle; (B) with respect to Performance Units, the Target Amount payable to each Participant; (C) with respect to Restricted Units and Restricted Stock, the Target Vesting Percentage for each Participant; and (D) subject to subsection (d) below, the criteria for computing the amount that will be paid or will vest with respect to each level of attained performance. The Committee will also set forth the minimum level of performance, based on the applicable Performance Measures, that must be attained during the Performance Cycle before any Long-Term Performance Award will be paid or vest, and the percentage of Performance Units that will become payable and the percentage of performance-based Restricted Units or Shares of Restricted Stock that will vest upon attainment of various levels of performance that equal or exceed the minimum required level.
|
(ii)
|
The Committee, in its discretion, may, on a case-by-case basis, reduce, but not increase, the amount of Long-Term Performance Awards otherwise payable to any Covered Employee with respect to any given Performance Cycle, provided, however, that no reduction will result in an increase in the dollar amount or number of Shares payable under any Long-Term Performance Award of another Covered Employee.
|
(e)
|
Payment, Certification.
Long-Term Performance Awards shall only be paid if the Committee certifies in writing the level of performance attained for the Performance Cycle in relation to the applicable Performance Measures. Long-Term Performance Awards awarded to Participants who are not Covered Employees will be based on the Performance Measures, or other applicable performance criteria, and payment formulas that the Committee, in its discretion, may establish for these purposes. These Performance Measures, or other performance criteria, and formulas may be the same as or different than the Performance Measures and formulas that apply to Covered Employees. In applying Performance Measures, the Committee (i) shall make adjustments for events listed in Section 5.3 in accordance therewith and (ii) may, in its discretion, exclude the effect of unusual or infrequently occurring items, including, but not limited to the following, as set forth in the Award Certificate or action of the Committee granting the Award: the cumulative effect of changes in the law, regulations or accounting rules, and other items, all determined in accordance with GAAP (to the extent applicable and unless specified otherwise in the Award Certificate or action of the Committee granting the Award) and identified in financial statements, notes to the financial statements or discussion and analysis of management; asset write downs; litigation or claim judgments or settlements; any reorganization and restructuring programs; acquisitions or divestitures; and foreign exchange gains and losses.; provided that the determination by the Committee that Performance Measures shall be adjusted for items in accordance with this clause (ii) shall be made no later than ninety (90) days after the commencement of any applicable Performance Cycle in respect of Long-Term Performance Awards awarded to Covered Employees.
|
(f)
|
Form of Payment.
Long-Term Performance Awards in the form of Performance Units may be paid in cash or full Shares, in the discretion of the Committee, and as set forth in the applicable Award Certificate. Performance-based Restricted Units and Restricted Stock will be paid in full Shares. Payment with respect to any fractional
|
(g)
|
Dividend Equivalents
. At the discretion of the Committee and as set forth in the applicable Award Certificate, dividend equivalents may be earned on Long-Term Performance Awards denominated in Shares, but only to the extent, and shall be payable only at the same time, as the underlying Long-Term Performance Awards may become earned, vested, and payable.
|
(h)
|
Special Vesting Provisions.
Unless the applicable Award Certificate provides otherwise, upon the death, Disability, Normal Retirement or a Change in Control Termination of a Participant who has an outstanding Long-Term Performance Award, the unvested Long-Term Performance Award will fully vest and be paid as if the Participant had continued in active employment with the Company through the date such Long-Term Performance Award would have vested and been paid in the absence of such event. Unless the applicable Award Certificate provides otherwise, upon the Termination of Employment of a Participant for any reason other than the Participant's death, Disability, Normal Retirement or a Change in Control Termination, the unvested Long-Term Performance Award will be forfeited unless the Participant qualifies for Early Retirement, in which case a pro rata portion of the Participant’s Long-Term Performance Awards will vest and be paid as if the Participant had continued in active employment with the Company through the date such Long-Term Performance Award would have vested and been paid in the absence of such event; provided that the number of Long-Term Performance Awards held by the Participant which shall vest under those circumstances shall equal the total number of Long-Term Performance Awards in which such Participant would have vested multiplied by a fraction, the numerator of which is the period of time (in whole months) that have elapsed since the date of grant, and the denominator of which is the number of total months set forth in the applicable Award Certificate for such Performance Period.
|
(a)
|
Vesting.
Restrictions on Other Stock-Based Awards granted under this Section 4.6 will lapse at such times and in such manner as determined by the Committee and set forth in the applicable Award Certificate. Unless the applicable Award Certificate provides otherwise, if the restrictions on Other Stock-Based Awards have not lapsed or been satisfied as of the Participant's Termination of Employment, the Shares will be forfeited by the Participant if the termination is for any reason other than the Normal Retirement, death or Disability of the Participant or a Change in Control Termination, except that the Award will vest pro rata with respect to the portion of the vesting term set forth in the applicable Award Certificate that the Participant has completed if the Participant qualified for Early Retirement. All restrictions on Other Stock-Based Awards granted pursuant to this Section 4.6 will lapse upon the Normal Retirement, death or Disability of the Participant or a Change in Control Termination.
|
(b)
|
Grant of Restricted Stock.
The Committee may grant Restricted Stock to any Employee, which Shares will be registered in the name of the Participant and held for the Participant by the Company. The Participant will have all rights of a shareholder with respect to the Shares, including the right to vote and to receive dividends or other distributions (subject to Section 4.6(e)), except that the Shares may be subject to a vesting schedule and will be forfeited if the Participant attempts to sell, transfer, assign, pledge or otherwise encumber or dispose of the Shares before the restrictions are satisfied or lapse.
|
(c)
|
Grant of Restricted Units.
The Committee may grant Restricted Units to any Employee, which Units will be paid in cash or whole Shares or a combination of cash and Shares, in the discretion of the Committee, when the restrictions on the Units lapse and any other conditions set forth in the Award Certificate have been satisfied. For each Restricted Unit that vests, one Share will be paid or an amount in cash equal to the Fair Market Value of a Share as of the date on which the Restricted Unit vests.
|
(d)
|
Grant of Deferred Stock Units.
The Committee may grant Deferred Stock Units to any Employee, which Units will be paid in whole Shares upon the Employee's Termination of Employment if the restrictions on the Units have lapsed. One Share will be paid for each Deferred Stock Unit that becomes payable.
|
(e)
|
Dividends and Dividend Equivalents.
At the discretion of the Committee and as set forth in the applicable Award Certificate, dividends paid on Shares may be paid immediately or withheld and deferred in the Participant's account. In the event of a payment of dividends on the Ordinary Shares, the Committee may credit Restricted Units with Dividend Equivalents in accordance with terms and conditions established in the discretion of the Committee. Dividend Equivalents will be subject to such vesting terms as is determined by the Committee and may be distributed immediately or withheld and deferred in the Participant's account as determined by the Committee and set forth in the applicable Award Certificate. Deferred Stock Units may, in the discretion of the Committee and as set forth in the Award Certificate, be credited with Dividend Equivalents or additional Deferred Stock Units. The number of any Deferred Stock Units credited to a Participant’s account upon the payment of a dividend will be equal to the quotient produced by dividing the cash value of the dividend by the Fair Market Value of one Share as of the date the dividend is paid. The Committee will determine any terms and conditions on deferral of a dividend or Dividend Equivalent, including the rate of interest to be credited on deferral and whether interest will be compounded.
|
(a)
|
Notwithstanding anything herein to the contrary, the Nominating Committee shall have the exclusive authority to issue awards to Directors who are not also employees of the Company or any Subsidiary (Director Awards), which may consist of, but not be limited to, Stock Options, Stock Appreciation Rights, or Other Stock-Based Awards. Each Director Award shall be governed by an Award Certificate approved by the Nominating Committee.
|
(b)
|
The Nominating Committee shall have the exclusive authority to administer Director Awards, and shall have the authority set forth in Section 3.2 and the indemnification set forth in Section 7.7, solely as such provisions apply to the Director Awards. All determinations made by the Nominating Committee hereunder shall be final, binding and conclusive.
|
(c)
|
Notwithstanding any other provision of the Plan to the contrary, the aggregate grant date Fair Market Value (computed as of the date of grant in accordance with applicable financial accounting rules) of all Awards granted to any Director during any single fiscal year (excluding Awards made at the election of the Director in lieu of all or a portion of annual and committee cash retainers) shall not exceed $____________.
|
(a)
|
The Shares issuable under the Plan will be authorized but unissued Shares, and, to the extent permissible under applicable law, Shares acquired by the Company, any Subsidiary or any other person or entity designated by the Company and held as treasury shares.
|
(b)
|
Subject to the counting rules set forth in Section 5.2 and adjustment in accordance with Section 5.3, the total number of Shares with respect to which Awards may be issued under the Plan shall be 17,769,489.
|
(c)
|
Incentive Stock Options may be granted under the Plan in respect of no more than 10 million Shares.
|
(a)
|
The total number of Shares with respect to which Awards may be issued under the Plan, as described in Section 5.1(b), shall be reduced by 2.2 Shares per each Share subject to an Award of Restricted Stock, Restricted Units, Deferred Stock Units, Performance Units or Other Stock-Based Awards, or as payment of an Annual Performance Bonus.
|
(b)
|
The following Shares related to Awards under the Plan will again be available for issuance under the Plan:
|
(i)
|
Shares related to Awards paid in cash; and
|
(ii)
|
Shares related to Awards that expire, are forfeited or cancelled or terminate for any other reason without issuance of Shares and any Shares of Restricted Stock that are returned to the Company upon a Participant’s Termination of Employment or, if applicable, a Director’s Termination of Directorship (including, for clarity, at a rate of 2.2 Shares per each Share related to such an Award in the form of Restricted Stock, Restricted Units, Deferred Stock Units, Performance Units or Other Stock-Based Awards, or as payment of an Annual Performance Bonus).
|
(c)
|
Any Shares issued in connection with Awards that are assumed, converted or substituted as a result of the acquisition of an Acquired Company by the Company or a combination of the Company with another company shall not count against the total number of Shares set forth in Section 5.1(b). Shares available under a stockholder approved plan of an Acquired Company (as appropriately adjusted to reflect the transaction) may be used for Awards under the Plan to individuals who were not employees or directors of the Company or a subsidiary prior to the transaction (subject to the stock exchange’s listing requirements)
|
(a)
|
Acceleration.
Unless the applicable Award Certificate provides otherwise, (i) all outstanding Stock Options and Stock Appreciation Rights will become exercisable as of the effective date of a Participant’s Change in Control Termination if the Awards are not otherwise vested, and all conditions will be waived with respect to outstanding Restricted Stock and Restricted Units (other than Long-Term Performance Awards) and Deferred Stock Units and (ii) each Participant who has been granted a Long-Term Performance Award that is outstanding as of the date of such Participant’s Change in Control Termination will be deemed to have achieved a level of performance, as of the Change in Control Termination, that would cause all (100%) of the Participant's Target Amounts to become payable and all restrictions on the Participant's performance-based Restricted Units and Shares of Restricted Stock to lapse. Unless the Committee determines otherwise in its discretion (either when an Award is granted or any time thereafter), in the event that Awards outstanding as of the date of a Change in Control that are payable in Ordinary Shares of the Company will not be substituted with comparable awards payable or redeemable in shares of publicly-traded stock after the Change in Control, each such outstanding Award (A) will become fully vested (at target, where applicable) immediately prior to the Change in Control and (B)(i) each such Award that is a Stock Option or Stock Appreciation Right with an exercise price below the Fair Market Value of the Shares subject to such Award will be settled in cash, without the Participant’s consent, for an amount equal to the amount that could have been attained upon the exercise of such Award immediately prior to the Change in Control had such Award been exercisable or payable at such time, and (ii) each such Award that is a Stock Option or Stock Appreciation Right with an exercise or grant price above the Fair Market Value of the Shares subject to such Award may be cancelled with no payment without the Participant’s consent.
|
(b)
|
Permissive Actions
. In addition to the actions described in Section 5.4(a)(A) and (B), in the event of a Change in Control, the Committee may take any one or more of the following actions with respect to any or all outstanding Awards, without the consent of Participants: (i) the Committee may determine that outstanding Stock Options and Stock Appreciation Rights shall be fully vested and exercisable and restrictions on Restricted Stock, Restricted Units, Deferred Stock Units and Other Stock-Based Awards shall lapse as of the date of the Change in Control or such other time (prior to a Participant’s Change in Control Termination) as the Committee determines; (ii) the Committee may require that a Participant surrender his or her outstanding Stock Options and Stock Appreciation Rights in exchange for one or more payments by the Company, in cash or Ordinary Shares, as determined by the Committee, in an amount equal to the amount by which the then Fair Market Value of the Shares subject to the Participant’s unexercised Stock Options and Stock Appreciation Rights exceeds the Exercise Price, if any, and on such terms as the Committee determines; (iii) after giving Participants an opportunity to exercise any outstanding Stock Options and Stock Appreciation Rights, the Committee may terminate any or all unexercised Stock Options and Stock Appreciation Rights at such time as the Committee deems appropriate; (iv) the Committee may determine that Annual Performance Bonuses and/or Long-Term Performance Awards will be paid out at their target level, in cash or Ordinary Shares as determined by the Committee; or (v) the Committee may determine that Awards that remain outstanding after the Change in Control shall be converted to similar grants of, or assumed by, the surviving corporation (or a parent or subsidiary of the surviving corporation or successor). Such acceleration, surrender, termination, settlement, payment or conversion shall take place as of the date of the Change in Control or such other date as the Committee determines. The Committee may specify how an Award will be treated in the event of a Change in Control either when the Award is granted or at any time thereafter.
|
(a)
|
The adoption of a resolution of the Board terminating the Plan; or
|
(b)
|
The day before the tenth (10
th
) anniversary of the approval of the Plan by the Company’s shareholders as described in Section 1.2.
|
(a)
|
Any Award may be transferred by will or by the laws of descent or distribution.
|
(b)
|
Unless the applicable Award Certificate provides otherwise, all or any part of a Nonqualified Stock Option or Shares of Restricted Stock may be transferred to a family member without consideration. For purposes of this subsection (b), "family member" includes any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the Participant, including adoptive relationships, any person sharing the Participant's household (other than a tenant or employee), a trust in which these persons have more than fifty percent (50%) of the beneficial interest, a foundation in which these persons (or the Participant) control the management of assets, and any other entity in which these persons (or the Participant) own more than fifty percent (50%) of the voting interests.
|
(c)
|
Unless the applicable Award Certificate provides otherwise, any Nonqualified Stock Option transferred by a Participant pursuant to subsection (b) may be exercised by the transferee only to the extent that the Award would have been exercisable by the Participant had no transfer occurred. The transfer of Shares upon exercise of the Award will be conditioned on the payment of any withholding tax.
|
(d)
|
Restricted Stock may be freely transferred after the restrictions lapse or are satisfied and the Shares are delivered, provided, however, that Restricted Stock awarded to an affiliate of the Company may be transferred only pursuant to Rule 144 under the Securities Act, or pursuant to an effective registration for resale under the Securities Act. For purposes of this subsection (d), "affiliate" will have the meaning assigned to that term under Rule 144.
|
(e)
|
In no event may a Participant transfer an Incentive Stock Option other than by will or the laws of descent and distribution.
|
(a)
|
Stock Options and Stock Appreciation Rights.
As a condition to the delivery of Shares pursuant to the exercise of a Stock Option or Stock Appreciation Right, the Committee may require that the Participant, at the time of exercise, pay to the Company by cash, certified check, bank draft, wire transfer or postal or express money order an amount sufficient to satisfy any applicable tax withholding obligations. The Committee may also, in its discretion, accept payment of the minimum tax withholding obligations through any of the Exercise Price payment methods described in Section 4.3(d).
|
(b)
|
Other Awards Payable in Shares.
The Participant shall satisfy the Participant's tax withholding obligations arising in connection with the release of restrictions on Restricted Units, Restricted Stock and Other Stock-Based Awards by payment to the Company in cash or by certified check, bank draft, wire transfer or postal or express money order, provided that the format is approved by the Company or a designated third-party administrator. However, subject to any requirements of applicable law, the Company may also satisfy the Participant's minimum tax withholding obligations by other methods, including selling or withholding Shares that would otherwise be available for delivery.
|
(c)
|
Cash Awards.
The Company may satisfy a Participant's tax withholding obligation arising in connection with the payment of any Award in cash by withholding cash from such payment.
|
(a)
|
Modifications to or Adjustments of Awards
. Any modifications to an Award pursuant to Subsection 3.2(g) or adjustments of an Award pursuant to Subsections 4.8 or 5.3 shall comply with the requirements of Section 409A.
|
(b)
|
Specified Employees
. Payments to any Participant who is a “specified employee” of deferred compensation that is subject to Code Section 409A(a)(2) and that becomes payable upon, or that is accelerated upon, such Participant’s Termination of Employment (as modified by Subsection 7.12(b)(iv)), shall not be made on or before the date which is six (6) months following such Participant’s Termination of Employment (or, if earlier, such Participant’s death). A specified employee for this purpose shall be determined by the Committee or its delegate in accordance with the provisions of Code Section 409A and the regulations and rulings thereunder.
|
|
|
||||
1.
|
I have reviewed this quarterly report on Form 10-Q of Mallinckrodt plc;
|
||||
|
|
||||
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
||||
|
|
||||
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
||||
|
|
||||
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
|
||||
|
|
||||
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
||||
|
|
|
|||
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
|||
|
|
||||
c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
||||
|
|
||||
d)
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
||||
|
|
||||
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
||||
|
|
||||
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
||||
|
|
||||
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Date: August 8, 2017
|
|
By:
|
/s/ Mark C. Trudeau
|
|
|
Mark C. Trudeau
|
|
|
|
President and Chief Executive Officer and Director
(principal executive officer)
|
|
|
||||
1.
|
I have reviewed this quarterly report on Form 10-Q of Mallinckrodt plc;
|
||||
|
|
||||
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
||||
|
|
||||
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
||||
|
|
||||
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
|
||||
|
|
||||
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
||||
|
|
|
|||
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
|||
|
|
||||
c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
||||
|
|
||||
d)
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
||||
|
|
||||
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
||||
|
|
||||
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
||||
|
|
||||
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Date: August 8, 2017
|
|
By:
|
/s/ Matthew K. Harbaugh
|
|
|
Matthew K. Harbaugh
|
|
|
|
Executive Vice President and Chief Financial Officer
(principal financial officer)
|
By:
|
/s/ Mark C. Trudeau
|
Mark C. Trudeau
|
|
President and Chief Executive Officer and Director
(principal executive officer)
|
By:
|
/s/ Matthew K. Harbaugh
|
Matthew K. Harbaugh
|
|
Executive Vice President and Chief Financial Officer (principal financial officer)
|